Page 11234..1020..»

Archive for the ‘Stem Cell Russia’ Category

Regenerative Stem Cells Knee Pain Treatment London, UK …

Wednesday, December 8th, 2021

The Regenerative therapy procedure is performed in an outpatient setting and only takes up to two hours. No general anaesthesia is required, and most patients dont need post-operative pain medication. After the procedure, patients typically return to work within a week or two and may resume physical activity much faster than after invasive surgery. Many patients report feeling marked improvement in their joint within one to three months.

For the procedure, PRP and cell concentrates are obtained from your body and prepared for injection. Once injected, cells follow inflammatory signals from damaged tissues and travel to the injured areas. These cells have multiple ways of repairing these damaged areas from inducing the production of natural anti-inflammatories which can assist with Osteoarthritis pain and swelling in the joint area to kick-starting the healing in injuries and stimulating regeneration. The anti-inflammatory effect lasts from 2-3 months. From there, you can see continued gradual improvement as the cells help provide healing to the affected area. However, you should not expect to see the full effect of the treatment earlier than six months, especially in the case of joint interventions. Variables like the type of disease or condition, age, lifestyle, comorbidities, general health and other factors also affect the outcome and length of recovery.

Visit link:
Regenerative Stem Cells Knee Pain Treatment London, UK ...

Read More...

Religious Groups Official Positions on Stem Cell Research …

Wednesday, December 8th, 2021

American Baptist Churches in the U.S.A.

The group has no explicit policy on the issue; rather it states that one must be guided by ones own relationship with God and Scripture.

Overview: Stem Cell Research at the Crossroads of Religion and PoliticsEmbryonic stem cell research, which uses cells found in three- to five-day-old human embryos to seek cures for a host of chronic diseases, has sparked a major debate in the United States.

The Science Behind Stem Cell ResearchStem cells, the building blocks of nature, can transform into any other type of cell in the body.

Public OpinionA March 2009 poll report from the Pew Research Center for the People & the Press finds that opinions about stem cell research have been fairly stable in recent years.

Religious Groups Official Positions on Stem Cell ResearchA breakdown of 17 major religious groups views on the issue.

Stem Cell Research Around the WorldThe U.S. is only one of many countries playing an important role in stem cell research.

Quotes on Stem Cell ResearchQuotes on stem cell research from political, religious and other prominent figures.

Though Buddhist teachings do not directly address the issue, there are two main tenets the prohibition against harming or destroying others (ahimsa), and the pursuit of knowledge (praja) and compassion (karua) that divide Buddhist scholars and communities. Some Buddhists argue that stem cell research is in accordance with the Buddhist tenet of seeking knowledge and ending human suffering, while others argue that it is a violation of the notion of not harming others.

In accordance with their anti-abortion stance, the U.S. Conference of Catholic Bishops supports adult stem cell research but opposes embryonic stem cell research since it creates or destroys human embryos.

The Church of Jesus Christ of Latter-day Saints has not issued a statement on the issue of stem cell research.

In 2004, the churchs governing body, the General Convention, declared itself in favor of stem cell research as long as the embryos used would have been destroyed otherwise, the embryos were not created solely for research purposes and the embryos were not bought or sold.

The ELCA does not have an official position on the issue. In 2005, the Churchwide Assembly, the governing body of the church, created a task force to study the issues of genetics and biotechnology and to present a report in 2011.

Though Hinduism believes that life begins at conception, the religion has no official position on stem cell research.

There is no explicit Islamic ruling on the issue of stem cell research. While some Muslim leaders allow for stem cell research on the ground that, according to Islam, an embryo in the early stage of pregnancy does not have a soul, others argue that the termination of an embryo at any stage of pregnancy is morally impermissible.

All major Jewish denominations including the Reform, Conservative, Orthodox and Reconstructionist movements support both embryonic and adult stem cell research as long as it is for medical or therapeutic purposes.

In 2005, the group reaffirmed its opposition to embryonic stem cell research, advocating instead for adult stem cell research.

In 2005, the National Association of Evangelicals issued a statement voicing its opposition to stem cell research.

After an evaluation in 2006 of the debate surrounding stem cell research, the National Council of Churches Human Biotechnologies Policy Development Committee adopted a position stating that as a result of a lack of clear consensus [among ethicists, academia and scientists], the National Council of Churches neither endorses nor condemns experimentation on human embryos.

In 2004, the Presbyterian Churchs governing body, the General Assembly, reaffirmed its position in favor of stem cell research that is intended to [restore health] to those suffering from serious illness.

In 1999, the Southern Baptist Convention reaffirmed its opposition to the destruction of human embryos [and] support for the development of alternative treatments which do not require human embryos to be killed.

In 2006, the associations policymaking body, the General Assembly, stated its support for stem cell research as long as the research is for medical therapies and not the reproductive cloning of humans.

In 2001, the United Church of Christ ruled in favor of research on embryonic stem cells that would otherwise be discarded from in vitro fertilization.

In 2004, the United Methodist Church asserted its support for therapeutic cloning in which spare embryonic stem cells resulting from in vitro fertilization are used. The church also maintained its opposition to the use or creation of embryonic stem cells solely for the purpose of research.

Read this article:
Religious Groups Official Positions on Stem Cell Research ...

Read More...

The Case Against Embryonic Stem Cell Research: An …

Wednesday, December 8th, 2021

Scientists largely agree that stem cells may hold a key to the treatment, and even cure, of many serious medical conditions. But while the use of adult stem cells is widely accepted, many religious groups and others oppose stem cell research involving the use and destruction of human embryos. At the same time, many scientists say that embryonic stem cell research is necessary to unlock the promise of stem cell therapies since embryonic stem cells can develop into any cell type in the human body.

In late 2007, researchers in the United States and Japan succeeded in reprogramming adult skin cells to act like embryonic stem cells. The new development offers the possibility that the controversy over the use of embryos could end. But many scientists and supporters of embryonic stem cell research caution that this advance has not eliminated the need for embryos, at least for the time being.

Recently, the Pew Forum sat down with Yuval Levin, author of Tyranny of Reason, to discuss the ethical and moral grounds for opposing embryonic stem cell research. Previously, Levin was the executive director of the Presidents Council on Bioethics. Currently, he is the Hertog Fellow at the Ethics and Public Policy Center in Washington, D.C., where he also directs the centers Bioethics and American Democracy program.

A counterargument explaining the case for embryonic stem cell research is made by Jonathan Moreno, a professor at the University of Pennsylvania and a senior fellow at the Center for American Progress in Washington, D.C.

Featuring:Yuval Levin, Hertog Fellow and Director of the Bioethics and American Democracy Program, Ethics and Public Policy Center

Interviewer:David Masci, Senior Research Fellow, Pew Forum on Religion & Public Life

Recently, researchers in the United States and Japan successfully turned human skin cells into cells that behave like embryonic stem cells. There has been some discussion that this advance makes the moral and ethical debate over embryonic stem cells moot. Do you think thats an accurate assessment?

I think its going to take a while for the ethical debate to catch up with the science. The scientific community has reacted very positively to this advancement, which was made in November 2007. There have been many additional scientific studies published on the topic since then, and it appears increasingly likely that the cells produced using skin cells are the equivalent of embryonic stem cells. So I think that, in time, this probably will be the final chapter of this particular debate about embryonic stem cells, but I dont think were at the end of it quite yet.

Do you agree with Professor James Thomson, who led the American research team that made this breakthrough, when he maintains that this advance does not, for the time being, abrogate the need for embryonic stem cell research?

Part of his argument for continuing to use embryonic stem cells was backward-looking to make the point that researchers wouldnt have been able to develop this technique if they hadnt been doing embryonic stem cell research. I think thats true, although in a certain way it actually vindicates the logic of President Bushs stem cell policy, which is to allow some work to be done without creating an incentive for the destruction of further embryos to advance the basic science in these kinds of directions.

Thomson also argued that there will still be a need to use embryos in the future. I think thats also a fair argument in the sense that there are always interesting things to learn from different kinds of experiments, but it doesnt address the ethical issues surrounding the debate. If there were no ethical concerns, then certainly the new development wouldnt mean embryonic research would become totally useless. But given that there are concerns, the case for destroying embryos does become a lot weaker. For some people, myself included, the ethical concerns are matters of principle and dont change with new developments.

But for a lot of people, the stem cell debate has always been a matter of balance. People are aware that there are ethical concerns and that there is enormous scientific promise. Now the debate is: Given the ethical questions at stake, is the scientific promise sufficient to make us put the ethical concerns aside and support the research? I think that balance has changed because of this advance, and having an alternative to embryonic stem cell research that achieves the same result will obviously affect the way people think about the ethics of this issue.

That doesnt mean the scientists no longer have any use for embryonic stem cells or even that they wont have any use for them. But I do think it means that people are going to change the way they reason about the balance between science and ethics because of this advance.

I know that you believe that human embryos have intrinsic worth. Do you believe that they have the same intrinsic worth as a five-year-old child or a 50-year-old man?

The question of intrinsic worth is complicated. I dont think it is right to try to determine an embryos intrinsic worth by debating when human life begins. The question of when life begins is a biological question, and the answer actually is fairly straightforward: The life of an organism begins at conception. The ethical question, however, is not about when a life begins but whether every life is equal, and thats a very different question.

I think that the embryonic stem cell debate is ultimately about the question of human equality. The United States has had one answer to that question written in its birth certificate the Declaration of Independence which states that all men are created equal. I think that examining this principle of human equality provides the right answer to this debate, but it is not a simple answer. Human equality doesnt mean that every person is the same or that every person can even be valued in the same way on every scale. What it means is that our common humanity is something that we all share. And what that means, in turn, is that we cant treat a human being in certain ways that we might non-human beings.

The protection of human life comes first. And to the extent that the debate is about whether it is acceptable to destroy a living human being for the purpose of science even for the purpose of helping other human beings I think that in that sense, the embryo is our equal. That doesnt mean that I would think of an embryo in the same way that I would think of a three-year-old child, but I would reject a technique that uses either of them for scientific experimentation.

So in other words, even though you would grieve the death of a 50-year-old man more than a five-day-old embryo, on at least the most basic level you believe that they both have the same right to life.

Yes, thats right. And right to life derives from human equality. The right to life is, in a way, drawn out of the political vocabulary of the Declaration of Independence. And so, to my mind, the argument at the heart of the embryonic stem cell debate is the argument about human equality.

Recently in The New Republic magazine, Harvard psychologist Steven Pinker wrote that conservative bioethicists like yourself consistently predict the worst when looking at developments in biotechnology. He went on to say that had there been a presidents council on cyber-ethics in the 1960s, no doubt it would have decried the threat of the Internet since it would inexorably lead to 1984 or computers taking over like HAL in 2001. How do you respond to this suggestion that there always seems to be this sort of chorus of doomsayers every time something new comes along?

To my mind, biotechnology is fundamentally different from past developments in technology because its directed to the human person. From the beginning of the scientific revolution, science and technology have tried to allow us to manipulate and shape the world around us for the benefit of man. Now that were beginning to manipulate and shape man, the question is: For the benefit of what? In some cases thats easy to see. Obviously curing disease is more of an old-fashioned scientific pursuit. But there are newer scientific developments, such as certain types of human enhancement technologies that raise very complicated questions of how we should judge the ends and the means of technological advancements. That being said, Pinker has a point, in a larger sense that judging the risks of new technologies is very difficult. In general, I think we ought to give the benefit of the doubt to our ability to use new technologies. I dont think that we should assume that the worst will happen. But there are specific instances, which are few but very important, when we do need to be cautious.

Lets shift gears to a question about religion and faith. Obviously there are people of faith on both sides of this debate. In fact, there are conservatives traditional social conservatives, such as Republican Sen. Orrin Hatch of Utah who support embryonic stem cell research. But could you explain how the Judeo-Christian and Western moral ethic informs your views on this issue and why you think that God is ultimately on your side?

Well, I dont know that I think that. My approach to this is not religious. Im not a particularly religious person and I come at this from more of a liberal democratic concern for human equality and the foundations of our society. That being said, those foundations are not utterly secular, and my understanding of them is not utterly secular. I think that to believe in human equality you do have to have some sense of a transcendent standard by which to make that judgment. In other words, when we talk about equality, what do we mean? Equal in relation to what?

Some people have certainly tried to make a purely secular liberal argument for human equality. While I think its very hard to ground a genuine, deep belief in human equality in a worldview that sees nothing above the material, I dont think that that belief depends on specific theological commitments. To my mind, its an American belief more than it is a religious belief.

Certainly I think that President Bushs commitment to human equality has a lot to do with a particular Christian sense of human worth and human value. But I dont think that its necessary to ground yourself in a particular theological or sectarian preference. I think that this is really about whether we believe in a liberal society, which comes from a belief in human equality. The American left, which for the most part is on the other side of this debate from where I am, has always been the champion of human equality, and I think that its a question that they have to really think about.

The Pew Forum and the Pew Research Center for the People & the Press have done polling on this issue over the last six or seven years and have found that Americans generally favor embryonic stem cell research. Why do you think this has happened, and what do you think this trend indicates?

Thats an interesting question. We actually did a poll here at the Ethics and Public Policy Center in February on a similar question, and the lesson I drew from that, and from some other polling thats been done, is that on the stem cell debate, people are just very confused about the facts, and the trend lines have generally followed the sense that cures are coming. In the end, the issue has been misrepresented as a choice between cures and Christianity, and people increasingly think that curing people like Christopher Reeve is just as much of a human good as protecting an embryo that they cant even imagine.

But when you dig down into peoples views about stem cell research, you find a great deal of confusion, and when you put the questions in ethical terms, you find small majorities opposing it. When you put the question in medical terms, you find, I think, somewhat larger majorities supporting it. In our poll, we asked the same people a series of questions that basically put the same issue in several different ways, and their responses are total opposites of one another. The fact that the same people come out on the opposite sides of the same issue when its put in different ways suggests to me that the issue is very hard to understand which it is.

Frequently one hears that, ultimately, you cant stop science or progress and that ethical, moral and religious objections inevitably will fall by the wayside when there are clear material gains to be made. Do you think thats the most likely scenario in this case, assuming the scientific community continues to see a need for embryonic stem cell research?

Well, thats the big assumption, right? To my mind, the aim of people such as myself has always been to find ways of doing the science without violating the ethics rather than to force a choice between the science and the ethics. If we force that choice, I think its more likely that the country would choose science over ethics, and thats exactly why we have to avoid the choice. I dont think we should be overconfident in our ability to persuade people to pass up a material benefit for an ethical principle, although I hope that can be done in the stem cell research debate. It certainly has been done in some instances when the principle was more evident and more obvious such as imposing limits on human subject research.

Again, the aim from my point of view and from a lot of people on my side of this argument has been to find ways to advance the science without violating the ethics. Thats the logic of President Bushs stem cell policy; thats why people have been pushing for alternatives; thats why theyre encouraging the development of these latest alternatives to avoid the choice, not to force the choice. I think thats the best thing for the country, from everybodys point of view. You dont want a situation where youve got sort of red-state medicine and blue-state medicine and people believe that the treatment their hospital is giving them is obtained in unethical ways. That would begin to break up the practice of medicine and to affect our attitudes about science which on the whole has done a tremendous amount of good for society. So I think what everybody should aim for is finding a way to end this potentially very damaging debate rather than force a choice.

This transcript has been edited for clarity, spelling and grammar.

Read more:
The Case Against Embryonic Stem Cell Research: An ...

Read More...

The mTOR Pathway in Pluripotent Stem Cells: Lessons for …

Wednesday, December 8th, 2021

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited.

Feature Papers represent the most advanced research with significant potential for high impact in the field. FeaturePapers are submitted upon individual invitation or recommendation by the scientific editors and undergo peer reviewprior to publication.

The Feature Paper can be either an original research article, a substantial novel research study that often involvesseveral techniques or approaches, or a comprehensive review paper with concise and precise updates on the latestprogress in the field that systematically reviews the most exciting advances in scientific literature. This type ofpaper provides an outlook on future directions of research or possible applications.

Editors Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world.Editors select a small number of articles recently published in the journal that they believe will be particularlyinteresting to authors, or important in this field. The aim is to provide a snapshot of some of the most exciting workpublished in the various research areas of the journal.

See the article here:
The mTOR Pathway in Pluripotent Stem Cells: Lessons for ...

Read More...

Hematopoietic Stem Cell Differentiation Pathways & Lineage …

Wednesday, December 8th, 2021

Hematopoietic stem cells (HSCs) are multipotent, self-renewing progenitor cells from which all differentiated blood cell types arise during the process of hematopoiesis. These cells include lymphocytes, granulocytes, and macrophages of the immune system as well as circulating erythrocytes and platelets. Classically, HSCs are thought to differentiate into two lineage-restricted, lymphoid and myelo-erythroid, oligopotent progenitor cells. An alternative, myeloid-based model for blood lineage development from HSCs describes a novel intermediary, a common myelo-lymphoid progenitor cell, which has the capacity to generate progeny from both lineages. The mechanisms controlling HSC self-renewal and differentiation are thought to be influenced by a diverse set of cytokines, chemokines, receptors, and intracellular signaling molecules. Differentiation of HSCs is regulated, in part, by growth factors and cytokines including colony-stimulating factors (CSFs) and interleukins (ILs) that activate intracellular signaling pathways. The factors depicted below are known to influence HSC multipotency, proliferation, and lineage commitment. HSCs and their differentiated progeny can be identified by the expression of specific cell surface lineage markers such as cluster of differentiation (CD) proteins and cytokine receptors.

To learn more, please visit our Hematopoietic Stem Cell Molecules Research Area.

Read the original here:
Hematopoietic Stem Cell Differentiation Pathways & Lineage ...

Read More...

Dutch stem cell biotech Neuroplast secures 10 million …

Wednesday, December 8th, 2021

GELEEN, Netherlands, Nov. 17, 2021 /PRNewswire/ -- Dutch clinical phase biotech Neuroplast raised a total of 10 million (US$ 11.5 million) in funding from investors Lumana Invest, Brightlands Venture Partners, LIOF, and from the Innovation Credit from the Netherlands Enterprise Agency, to further advance the clinical development of a transformative treatment for Traumatic Spinal Cord Injury (TSCI). Neuroplast will use this Series B funding to obtain conditional EMA market approval for its Neuro-Cells stem cell therapy.

Annually, approximately 29,000 people across Europe and the USA suffer from acute Traumatic Spinal Cord Injury (TSCI), for which effective treatment is currently unavailable. Patients usually experience life-long disability and dependence, with a negative impact on quality of life. Furthermore, associated costs for society at large are estimated at over 11.4 billion ($13 billion) per year.

With the aim of giving back perspective to people that suffer from primarily inflammation-driven neurological disorders, Neuroplast has developed Neuro-Cells, a treatment that uses the patient's own stem cells to prevent (further) loss of function during the acute phase after sustaining damage to the spinal cord, to save mobility and independence.

Marcel Kloosterman, Managing Partner at Brightlands Venture Partners (BVP), states:

"The science behind Neuroplast's technology platform is truly groundbreaking.A future in which patients can make smart use of their own cells to put a stop to further neurological damages and improve potential regeneration is getting closer and closer.For BVP it is a thrill to be part of that fascinating journey."

Neuroplast acquired a GMP1 license and received a European Orphan Designation2 that allows fast-track development. Furthermore, it has already successfully completed a clinical Phase I trial, in collaboration with Hospital Nacional de Parapljicos in Spain, that confirmed safety and tolerability, without product-related adverse events. The Dutch Limburg-based biotech is currently preparing for an international multi-center randomized placebo-controlled Phase II study.

Tys van Elk, Director at LIOF, adds:

"Our mission is to move together towards a smarter, more sustainable, and healthier Limburg. We are pleased to see that the life sciences and health ecosystem in Limburg is a successful breeding ground for innovative companies like Neuroplast, that can really make impact."

Neuroplast will use the 10M (US$ 11.5M) Series B funding to take the next steps towards conditional EMA market approval for TSCI, which includes running Phase II and III trials, consulting the EMA and executing a Health Technology Assessment.

Next to the funded pathway for TSCI, Neuroplast aspires to explore applicability of the Neuro-Cellstechnology platform to other therapeutic areas.

Wim Smit, Managing Director at Lumana Invest, comments:

"We are not only excited about the clinical progress of Neuro-Cells treatment for TSCI, but also about the outlook of the technology to other conditions, such as Traumatic Brain Injury."

Vincent The, Chief Financial Officer at Neuroplast, concludes:

"This funding enables us to complete the Neuro-Cells development pathway for TSCI. With the recent successful completion of our Phase I study, we now have both a good clinical as well as a solid financial foundation in place. This puts us in a great position to start exploring the broader potential of the Neuro-Cells technology platform for other primarily inflammation-driven neurological disorders. For these activities, we are seeking complementary investment."

About Traumatic Spinal Cord Injury

Acute TSCI causes incurable impairment to the spinal cord, affecting approximately 12,000 people across Europe and 17,000 across the USA annually. The damage or trauma interrupts communication of the brain with the body regions below the site of injury. Spinal cord injuries are mainly caused by accidents and - in most of the cases - result in life-long loss of control of motor functions and sensations. After the primary injury to the spinal cord, a cascade of events leads to progressive loss of tissue which may further deteriorate the patient's prognosis. Current treatment approaches for TSCI are only symptomatic, leaving the underlying pathophysiology unchanged.

TSCI has a serious impact on the quality of life of patients, with severe implications on mobility and loss of independence. In addition, TSCI creates a lifetime financial burden for patients, payors, healthcare systems and societies at large.

About Neuro-Cells

Neuro-Cells is a transformative treatment under GMP in the crucial first phase after sustaining TSCI, during which the irreversible impact of TSCI can be radically reduced. It contains non-substantially manipulated bone marrow-derived hematopoietic and mesenchymal stem cells, manufactured from a patient's own bone marrow (donor and receiver are the same person). Inflammatory inducing components and pathogens are removed during this process.

About Neuroplast

Neuroplast is a Dutch stem cell technology company focusing on fast-track development programs using autologous cell products for treatment of primarily inflammation-driven neurological disorders, with the aim of giving back perspective to people who suffer from those conditions.

The company was founded in August 2014 by physician Johannes de Munter and neurologist Erik Wolters. Current investors are Lumana Invest, Brightlands Venture Partners, LIOF and the Netherlands Enterprise Agency. Neuroplast is located in Brightlands Chemelot Campus in The Netherlands.

About Lumana Invest

Investment company Lumana was established by entrepreneurs and unique due to not having a predetermined investment horizon. The Lumana founders showcase strong commitment to their portfolio companies by actively supporting management in strategic decision making.

About Brightlands Venture Partners

Brightlands Venture Partners is the fund manager of BVP Fund IV and is a so-called ecosystem investor. BVP invests in companies benefiting from and contributing to the Brightlands campuses in the south of The Netherlands. Other funds under management are Chemelot Ventures, Brightlands Agrifood Fund and Limburg Ventures. BVP Fund IV focuses on sustainability and health and is the successor fund of the 2014 vintage Chemelot Ventures; together the funds have made over 40 investments.

About LIOF

LIOF is the regional development agency for Limburg and supports innovative entrepreneurs with advice, network and financing. Together with entrepreneurs and partners, LIOF is working towards a smarter, more sustainable and healthier Limburg by focusing on the transitions of energy, circularity, health and digitalization.

About The Netherlands Enterprise Agency

The Netherlands Enterprise Agency operates under the auspices of the Dutch Ministry of Economic Affairs and Climate Policy. It facilitates entrepreneurship, improves collaborations, strengthens positions and helps realize national and international ambitions with funding, networking, know-how and compliance with laws and regulations.

Forward looking statements

All statements other than statements of historical facts, including the statements about the clinical and therapeutic potential and future clinical milestones of Neuro-Cells, the indications we intend to pursue and our possible clinical or other business strategies, and the timing of these events, are forward-looking statements. Forward-looking statements can be identified by terms such as "believes", "expects", "plans", "potential", "would" or similar expressions and the negative of those terms. These forward-looking statements are based on our management's current beliefs and assumptions about future events and on information currently available to management. Neuroplast B.V. does not make any representation or warranty, express or implied, as to the improper use of this article, accuracy, completeness or updated status of above-mentioned statements. Therefore, in no case whatsoever will Neuroplast B.V. be legally liable or liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.

In case of any further questions, please contact:

Neuroplast Sasja VerhoogT: +31 (0)85 076 1000E: [emailprotected]

LifeSpring LifeSciences Communication, AmsterdamLeon MelensT: +31 6 538 16 427E: [emailprotected]

1Good Manufacturing Practice (GMP) describes the minimum standards that a medicines manufacturer must meet in their production processes, under inspections coordinated by EMA

2An Orphan Designation (OD) is a designation for treatments of rare conditions, that allows fast-track clinical research

SOURCE Neuroplast

View post:
Dutch stem cell biotech Neuroplast secures 10 million ...

Read More...

Stem Cell Banking Market Size 2021, Latest Business Opportunities, Growth Statistics, Industry Share, Upcoming Trends, Covid-19 Impact, Demand…

Wednesday, December 8th, 2021

Report Ocean presents a new report on Stem Cell Banking Market size, share, growth, industry trends, and forecast 2030, covering various industry elements and growth trends helpful for predicting the markets future. The global stem cell banking market size was US$ 2.2 billion in 2020. The global stem cell banking market is forecast to reach the value of US$5.5 billion by 2030 by growing at a compound annual growth rate (CAGR) of 9.6% during the forecast period from 2021-2030. Stem cell banking is a process of collecting, extorting, and freezing cord blood for future use. Cord blood stem cells are used in the treatment of blood-related diseases, including thalassemia, sickle cell disease, and leukemia.

Request To Download Sample of This Strategic Report@

https://reportocean.com/industry-verticals/sample-request?report_id=Pol56

In order to produce a holistic assessment of the market, a variety of factors is considered, including demographics, business cycles, and microeconomic factors specific to the market under study. Stem Cell Banking Market report 2021 also contains a comprehensive business analysis of the state of the business, which analyzes innovative ways for business growth and describes critical factors such as prime manufacturers, production value, key regions, and growth rate.

The Centers for Medicare and Medicaid Services report that US healthcare expenditures grew by 4.6% to US$ 3.8 trillion in 2019, or US$ 11,582 per person, and accounted for 17.7% of GDP. Also, the federal government accounted for 29.0% of the total health expenditures, followed by households (28.4%). State and local governments accounted for 16.1% of total health care expenditures, while other private revenues accounted for 7.5%.

This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges, that will determine the markets future growth.

Request To Download Sample of This Strategic Report@https://reportocean.com/industry-verticals/sample-request?report_id=Pol56

Factors Influencing

The global stem cell banking market is forecast to gain traction, owing to the growing prevalence of blood-related diseases, rising healthcare expenditure, and favorable government initiatives to enhance the services in the healthcare sector.

The rising awareness regarding the therapeutic potential of stem cells treatment is forecast to fuel the growth of the global stem cell banking market.

The increasing approval for research activities and trials in the stem cell industry would create lucrative opportunities for market growth during the analysis period.

The growing development of advanced technologies for stem cell preservation, storage, and processing is forecast to create favorable growth opportunities for the market players in the global stem cell banking market.

Companies initiatives to increase awareness regarding the benefits of stem cells are forecast to accelerate the market growth in the coming years. CordBloodAwareness.org was created in the United States to spread awareness regarding umbilical cord blood stem cells.

Get a Sample PDF copy of the report@

https://reportocean.com/industry-verticals/sample-request?report_id=Pol56

Geographic Analysis

Geographically, North America is forecast to lead in the global stem cell banking market because of the rising awareness regarding stem cell banking services and technological advancement in the industry. In addition, increasing demand for stem cell transplantation procedures is accelerating the regional growth in the global stem cell banking market. Furthermore, government initiatives to enhance healthcare infrastructure should create promising opportunities for the market players in the stem cell banking industry.

Asia-Pacific is forecast to grow with a significant compound annual growth rate. The increasing population awareness regarding the therapeutic benefits of stem cell banking is the primary factor driving the market growth. Moreover, government initiatives for improving healthcare infrastructure would propel the regions contribution.

COVID-19 Impact Analysis

The global stem cell banking market witnessed a slight slow down during the pandemic as preferences shifted to curbing the COVID-19 spread. Moreover, people avoided vising hospitals for stem cell treatment as it increases the chances of risk. Surgeons and doctors also postponed other treatments, as the entire healthcare sector was overburdened by the COVID-19 patients. Thus, the stem cell banking market witnessed a slight decline during the pandemic.

Get a Sample PDF copy of the report@

https://reportocean.com/industry-verticals/sample-request?report_id=Pol56

Competitors in the Market

Cord Blood Registry System

Cordlife Group Limited

Cryo-Cell International

Cryo-Save AG

LifeCell International

StemCyte

ViaCord

Global Cord Blood

Smart Cells International

Vita34

CryoHoldco

Other prominent players

Market segmentation

By Service Type

Collection & Transportation

Processing

Analysis

Storage

By Utilization

Used

Unused

By Cell Type

Umbilical Cord Stem Cell

Cord Blood

Cord Tissue

Placenta

Adult Stem Cell

Embryonic Stem Cell

By Bank Type

Public

Private

Ask for Customization@

https://reportocean.com/industry-verticals/sample-request?report_id=Pol56

By Region

North America

The U.S.

Canada

Mexico

Europe

Western Europe

The UK

Germany

France

Italy

Spain

Rest of Western Europe

Eastern Europe

Poland

Russia

Rest of Eastern Europe

Asia Pacific

China

India

Japan

Australia & New Zealand

ASEAN

Rest of Asia Pacific

Middle East & Africa (MEA)

UAE

Saudi Arabia

South Africa

Rest of MEA

South America

Brazil

Argentina

Rest of South America

What are the aspects of this report that relate to regional analysis?

The reports geographical regions include North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.

The report provides a comprehensive analysis of market trends, including information on usage and consumption at the regional level.

Reports on the market include the growth rates of each region, which includes their countries, over the coming years.

How are the key players in the market assessed?

This report provides a comprehensive analysis of leading competitors in the market.

The report includes information about the key vendors in the market.

The report provides a complete overview of each company, including its profile, revenue generation, cost of goods, and products manufactured.

The report presents the facts and figures about market competitors, alongside the viewpoints of leading market players.

A market report includes details on recent market developments, mergers, and acquisitions involving the key players mentioned.

What is the key information extracted from the report?

Read the original:
Stem Cell Banking Market Size 2021, Latest Business Opportunities, Growth Statistics, Industry Share, Upcoming Trends, Covid-19 Impact, Demand...

Read More...

Removal of sanctions major reason for Iran’s signature on JCPOA – Tehran Times

Wednesday, December 8th, 2021

Chabahar Port is not only a transit port, it is an investment opportunity, the Iranian ambassador in India said in a recent interview with ThePrint, a Delhi-based online newspaper.

Ali Chegani pointed out that Indian External Affairs Minister Subrahmanyam Jaishankar has visited Iran twice after the presidency of Seyed Ebrahim Raisi and added that a visit by his Iranian counterpart Hussain Amir Abdollahian to New Delhi is in the pipeline.

The Iranian envoy pointed out the Chabahar Port is not subject to U.S. unilateral sanctions. Pundits believe that an exemption was granted due to the U.S. focus on containing the emerging Chinese influence in the region. The Pakistani Port of Gwadar, which lies 140 kilometers east of Chabahar, is being developed by China as part of the China-Pakistan Economic Corridor.

In May 2015, Iran and India signed a cooperation agreement for the development of Chabahar port. Indias private sector was scheduled to invest in Chabahar in two phases.

The first phase is a $31 billion project that involves construction of two berths in the port, a container of 640 meters and a multipurpose cargo terminal of 600 meters.

In the second phase, Indias Jindal Infrastructure, Essar, SAIL and IRCON will develop the area around the port which involves developing a free trade zone and a railway line connecting landlocked Afghanistan to the Central Asian region.

For India, one of the fastest growing economies in the world, Chabahar Port will provide an alternative route to conduct business with Afghanistan and Central Asia circumventing Pakistan.

Iran has built an alliance with the East, including China, Russia and regional countries

In January 2017, seven agreements valued at over $3bn were signed by Iranian, Indian, Omani, Chinese, and South Korean investors to promote investment opportunities and sustainable development in Mokran coast in Chabahar Free Trade Zone (CFTZ).

However, all foreign investors exited from Chabahar project due to U.S. withdrawal from the JCPOA and imposition of maximum pressure sanctions in 2018. In total 1,500 sanctions were legislated during the former U.S. President Donald Trumps administration. These restrictions make financial transactions almost impossible. Worth mentioning is also that the foreign investors could be subject to secondary sanctions.

With the ongoing seventh round of the JCPOA talks which resumed on November 29, the Western powers must keep in mind what kind of economic doldrums the Iranian middle and lower class are going through due to sanctions along with the COVID-19 pandemic. The Raisi administration has emphasized sanctions removal is a prerequisite for revival of the nuclear deal.

Humanitarian imports were allowed under the maximum pressure sanctions instituted by Trump. Due to lack of a stable banking channel for humanitarian work Iran is unable to import drugs, medical equipment, etc. in this pandemic era.

When the U.S. exited the JCPOA in 2018, the so-called E3 (Germany, France and UK) registered the Instrument in Support of Trade Exchanges (INSTEX). However, this special purpose vehicle (SPV) has no engine or driver. INSTEX mechanism was supposed to keep trade flow between Europe and Iran and initially it was announced that this SPV would be used for sectors most essential, such as pharmaceutical, medical devices, and agri-food goods. However, this SPV remains without a driver and engineless.

The Norwegian Refugee Council warned recently that future aid work is at risk in Iran due to the U.S. sanctions. The delivery of aid to Afghan refugees residing in Iran and for the 2019s severe flooding victims in Iran was at risk because banks are refusing to transfer money to aid agencies due to fear of sanctions, says the Norwegian group.In April 2019 severe and widespread flash flooding forced 366,000 people from their homes, and killed 76 people in 25 of 31 provinces in Iran. With infrastructure facilities and livelihoods hit hard, immediate and long-term assistance and support for over two million people was hampered due to sanctions.

In an address to the UN on November 9, Irans ambassador to the United Nations, Majid Takht Ravanchi, denounced the unilateral sanctions for barring the affected countries from gaining access to financial resources needed for achieving the goals of sustainable development. Ravanchi pointed out that issues such as exclusion and inequality can act as potential drivers, aggravating factors for conflicts and weaken opportunities in achieving lasting peace.

When Raisi took office he promised to take action to lift harsh sanctions and bridge the gap with dissatisfied Iranian general public but emphasized that he will not tie the countrys future to the West. Raisi said instead his administration will prioritize regional ties, especially with neighboring countries.

Iran has built an alliance with the East, including China, Russia and regional countries. Raisis promise of prioritizing relations with the regional countries has borne fruit. Irans membership of the SCO was one of the limelight, but the process of membership started years ago and it will take another two years for the institution of Irans full membership.

Another example is Raisis visit to Ashgabat, Turkmenistan, on November 28. During the trip an agreement was signed for gas swaps between Iran, Azerbaijan and Turkmenistan. Petroleum Minister Javad Owji said the shipments are due to begin on December 22. This happened at the backdrop of the recent rocky diplomatic road between Iran and Azerbaijan.

Meanwhile, there have been several rounds of talks between Iranian and Saudi Arabian officials. Both sides have expressed optimism over the talks and future rounds are in the pipeline which could bring the two main players of the region closer.

The Iran-China Strategic Agreement deal was signed on March 27, 2021, on the 50th anniversary of the establishment of diplomatic relations between Iran and China. Although the details and terms of the agreement originally proposed in 2016 have not been made public, it has been announced that China will invest $400-600 billion into the Iranian economy, reads an article by China Briefing. In return for the Chinese help Iran will provide cheap oil. The two countries also signed defense agreements and conducted naval exercises during the Rouhani years.

This is the first time that the Islamic Republic has reached such an extensive deal with a major world power. The last one was a 10-year agreement with Russia, which was later extended to 20 years.

What will be the impact of the Iran-China strategic deal on the development of Chabahar remains to be seen.

With the continuation of the sanctions regime, Irans so-called shift to the East is inevitable. China and Russias role in the development of Chabahar Free Trade Zone is inevitable.

Chinas new digital currency e-RMB along with barter trade could play an important role to facilitate Sino-Iranian trade, reducing regional reliance on greenback transactions.However, returning full-circle back to todays economic realities, the U.S. dollar remains the most important and influential currency in the current financial market. In 2019, the U.S. dollar made up nearly 90 percent of all international transactions and 60 percent of all foreign exchange reserves. The supremacy of the U.S. dollar gives U.S. economic sanctions their strength, making it nearly impossible for sanctioned nations such as Iran and North Korea to conduct international business.

In a recent telephone conversation, Raisi told his Russian counterpart Vladimir Putin that the Islamic Republic is absolutely serious about negotiations and we are equally serious about our people rights to have sanctions lifted, according to a statement published on the presidencys website.

The moment the sanctions regime vanishes Iran will become one of the most lucrative places in the world to invest. Apart from natural resources, Iran is also a major global producer of steel, cement, cars and well positioned in nanotechnology and stem cell research.

All efforts should be made during the seven round of the Vienna talks to facilitate the legal rights of the Iranian nation to benefit from peaceful nuclear knowledge.

Describing Iran's potential, Sajid Rizvi, editor-in-chief of the London-based EAPGROUP International Media, said, It's very hard to beat its roll call of assets: a consumer market of more than 80 million, largely well educated people; a human capital mix that is even more attractive than Turkey; and in the all important energy front, a combination of as much oil as Saudi Arabia, as much gas as Russia, and arguably more mineral resources than Australia.

More:
Removal of sanctions major reason for Iran's signature on JCPOA - Tehran Times

Read More...

Primary Cells Market Research Report by Origin, by Cell Type, by End-user, by Region – Global Forecast to 2026 – Cumulative Impact of COVID-19 – Yahoo…

Wednesday, August 4th, 2021

Primary Cells Market Research Report by Origin (Animal Primary Cells and Human Primary Cells), by Cell Type (Dermatocytes, Gastrointestinal Cells, and Heart Cells), by End-user, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

New York, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Primary Cells Market Research Report by Origin, by Cell Type, by End-user, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06087175/?utm_source=GNW

The Global Primary Cells Market size was estimated at USD 1,025.78 Million in 2020 and expected to reach USD 1,144.46 Million in 2021, at a Compound Annual Growth Rate (CAGR) 11.90% from 2020 to 2026 to reach USD 2,014.78 Million by 2026.

Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:This research report categorizes the Primary Cells to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Origin, the Primary Cells Market was studied across Animal Primary Cells and Human Primary Cells.

Based on Cell Type, the Primary Cells Market was studied across Dermatocytes, Gastrointestinal Cells, Heart Cells, Hematopoietic Cells, Hepatocytes, Lung Cells, Musculoskeletal Cells, and Renal Cells. The Hepatocytes is further studied across Cryopreserved Hepatocytes and Fresh Hepatocytes.

Based on End-user, the Primary Cells Market was studied across Life Science Companies and Research Institutes.

Based on Geography, the Primary Cells Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Primary Cells Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Primary Cells Market, including AcceGen, Allcells, American Type Culture Collection, Axol Bioscience Ltd., BioIVT, Biopredic International, BPS Bioscience, Inc., Cell Biologics, Inc., Corning Incorporated, Creative Bioarray, Epithelix SRL, Ixcells Biotechnologies, Lonza Group AG, Merck KGaA, Neuromics, Ppa Research Group, Inc., Promocell GmbH, Reachbio LLC, Sciencell Research Laboratories, Inc., Sekisui Xenotech, LLC, Stem Cell Technologies, Inc., StemExpress, LLC, Thermo Fisher Scientific, Inc., and Zenbio, Inc..

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:1. What is the market size and forecast of the Global Primary Cells Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Primary Cells Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Primary Cells Market?4. What is the competitive strategic window for opportunities in the Global Primary Cells Market?5. What are the technology trends and regulatory frameworks in the Global Primary Cells Market?6. What is the market share of the leading vendors in the Global Primary Cells Market?7. What modes and strategic moves are considered suitable for entering the Global Primary Cells Market?Read the full report: https://www.reportlinker.com/p06087175/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

View post:
Primary Cells Market Research Report by Origin, by Cell Type, by End-user, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19 - Yahoo...

Read More...

Global Stem Cell Assay Market growth will help industry players with different potential opportunities to explore the market 2021-2027 The Manomet…

Wednesday, August 4th, 2021

TheStem Cell Assay market report offers insights about the marketstatistics based on data collected fromprimary and secondary researchby industry experts. The Global Stem Cell Assay market analysis report gives a detailed overview of the Stem Cell Assay sector, market segmentation, competitive analysis, and major industry developments. The Stem Cell Assay market research study is structured by the latest and most sophisticated methods to capture, process, measure, and evaluate market data. The Stem Cell Assay market report assesses the changing competitive fundamentals based on key market factors. The Stem Cell Assay market forecasts are offered based on historical and future prospects of supply and demand.also, representing the Stem Cell Assay Market Factor Analysis-Porters Five Forces, Supply/Value Chain, PESTEL analysis, CAGR value, product offerings, company landscape analysis, Market Entropy, CAPEX cycle, COGS Analysis, EBITDA analysis,Patent/Trademark Analysis, andPost COVID Impact Analysis.Key Leading Players having extreme Growth Rate in last Few decades includedGE Healthcare, Promega Corporation, Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, Bio-Techne Corporation, Cellular Dynamics International, Cell Biolabs, Hemogenix, Stemcell Technologies.The analysis has listed and evaluated all the key players in the Global Stem Cell Assay Market Compared them on the basis of different metrics such as annual sales shipments volume, historical growth rates, market revenue, and marketing strategies.This Stem Cell Assay industry study report proposes strategic plans to improve market positions for existing market participants.

In addition, the report will also include the computed expected CAGR of the Stem Cell Assay market on the grounds of the prevailing and earlier records in relation to the global market. Moreover, it also offers pin-point analysis for altering the competitive dynamics of the market that can further help in decision-making. It also assists in recognizing the key products and their growth potential during the projected period.

Download Free PDF Sample Report Here:-https://www.syndicatemarketresearch.com/sample/stem-cell-assay-market

( We are Providing a Free Sample copy as per your Research Requirement, also including Covid 19 impact analysis )

Dont miss out on the Analysis of business opportunities in the Stem Cell Assay Market. Speak to our analysts and gain vital industry insights that will help you for your business growth.

Syndicatemarketresearch analysts cover all key parameters required for COVID-19 effect on the business industry, economic implications their trends, factors, consumer behavior on shopping, the effect on spending lot of money on advertising and also on useful industries like medical, transportation, food and Beverage.The globally rising of the Bio crisis COVID-19 has many businesses are struggling and confused on what steps to take to minimize or maximize the economic impact.

Some of the key companies profiled in the global Stem Cell Assay market report include:GE Healthcare, Promega Corporation, Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, Bio-Techne Corporation, Cellular Dynamics International, Cell Biolabs, Hemogenix, Stemcell Technologies

Major parameters covered under these company profiles include revenues, gross profits, operating income, COGS, EBITDA, sales volume, product offerings, company landscape analysis, key strategic moves, key recent developments, and technological roadmap.

The global Stem Cell Assay market has been segmented in the following manner:

By Type:Dermatology Stem Cell Assay, Cardiovascular Stem Cell Assay, Central Nervous System Stem Cell Assay, Oncology Stem Cell Assay, Other

By Application:Regenerative Medicine & Therapy Development, Drug Discovery and Development, Clinical Research, Other

Key regions covered in the world Stem Cell Assay market report include:

The five regions are in a turned segment into major countries and geographies. The key countries included in the global Stem Cell Assay market report includeU.S., Canada, Germany, UK, Italy, France, Spain, China, India, Southeast Asia countries, South Korea, Japan, Australia, GCC countries, Turkey, Brazil, Egypt, Mexico, and South Africa among others.

The main objective of the whole market research report is to help the customer understand business in terms of scope, growth potential, fragmentation, opportunities, key market developments, changing consumer preferences, and new technological trends in the Stem Cell Assay market. The Stem Cell Assay market evaluation report consists of historical and forecasted market data shown by pie charts, maps, graphs, and Phased opportunity analysis in the study.

Key take aways from the report:

To get Free Consultation about Report, Do Inquiry Here @https://www.syndicatemarketresearch.com/inquiry/stem-cell-assay-market

Reasons to buy the global Stem Cell Assay market report:

TOC of Report include-

1 Study Coverage1.1 Stem Cell Assay Product1.2 Key Market Segments in This Study1.3 Key Manufacturers Covered1.4 Market by Type1.4.1 Global Stem Cell Assay Market Size Growth Rate by Type (Dermatology Stem Cell Assay, Cardiovascular Stem Cell Assay, Central Nervous System Stem Cell Assay, Oncology Stem Cell Assay, Other)1.5 Market by Application1.5.1 Global Stem Cell Assay Market Size Growth Rate by Application (Regenerative Medicine & Therapy Development, Drug Discovery and Development, Clinical Research, Other)1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Stem Cell Assay Market Size2.1.1 Global Stem Cell Assay Revenue 2013-20252.1.2 Global Stem Cell Assay Production 2013-20252.2 Stem Cell Assay Growth Rate (CAGR) 2018-20252.3 Analysis of Competitive Landscape2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)2.3.2 Key Stem Cell Assay Manufacturers2.3.2.1 Stem Cell Assay Manufacturing Base Distribution, Headquarters2.3.2.2 Manufacturers Stem Cell Assay Product Offered2.3.2.3 Date of Manufacturers Enter into Stem Cell Assay Market2.4 Key Trends for Stem Cell Assay Markets & Products

3 Market Size by Manufacturers3.1 Stem Cell Assay Production by Manufacturers3.1.1 Stem Cell Assay Production by Manufacturers3.1.2 Stem Cell Assay Production Market Share by Manufacturers3.2 Stem Cell Assay Revenue by Manufacturers3.2.1 Stem Cell Assay Revenue by Manufacturers (2013-2018)3.2.2 Stem Cell Assay Revenue Share by Manufacturers (2013-2018)3.3 Stem Cell Assay Price by Manufacturers3.4 Mergers & Acquisitions, Expansion Plans

4 Stem Cell Assay Production by Regions4.1 Global Stem Cell Assay Production by Regions4.1.1 Global Stem Cell Assay Production Market Share by Regions4.1.2 Global Stem Cell Assay Revenue Market Share by Regions4.2 United States4.2.1 United States Stem Cell Assay Production4.2.2 United States Stem Cell Assay Revenue4.2.3 Key Players in United States4.2.4 United States Stem Cell Assay Import & Export4.3 Europe4.3.1 Europe Stem Cell Assay Production4.3.2 Europe Stem Cell Assay Revenue4.3.3 Key Players in Europe4.3.4 Europe Stem Cell Assay Import & Export4.4 China4.4.1 China Stem Cell Assay Production4.4.2 China Stem Cell Assay Revenue4.4.3 Key Players in China4.4.4 China Stem Cell Assay Import & Export4.5 Japan4.5.1 Japan Stem Cell Assay Production4.5.2 Japan Stem Cell Assay Revenue4.5.3 Key Players in Japan4.5.4 Japan Stem Cell Assay Import & Export4.6 Other Regions4.6.1 South Korea4.6.2 India4.6.3 Southeast Asia

5 Stem Cell Assay Consumption by Regions5.1 Global Stem Cell Assay Consumption by Regions5.1.1 Global Stem Cell Assay Consumption by Regions5.1.2 Global Stem Cell Assay Consumption Market Share by Regions5.2 North America5.2.1 North America Stem Cell Assay Consumption by Application5.2.2 North America Stem Cell Assay Consumption by Countries5.2.3 United States5.2.4 Canada5.2.5 Mexico5.3 Europe5.3.1 Europe Stem Cell Assay Consumption by Application5.3.2 Europe Stem Cell Assay Consumption by Countries5.3.3 Germany5.3.4 France5.3.5 UK5.3.6 Italy5.3.7 Russia5.4 Asia Pacific5.4.1 Asia Pacific Stem Cell Assay Consumption by Application5.4.2 Asia Pacific Stem Cell Assay Consumption by Countries5.4.3 China5.4.4 Japan5.4.5 South Korea5.4.6 India5.4.7 Australia5.4.8 Indonesia5.4.9 Thailand5.4.10 Malaysia5.4.11 Philippines5.4.12 Vietnam5.5 Central & South America5.5.1 Central & South America Stem Cell Assay Consumption by Application5.5.2 Central & South America Stem Cell Assay Consumption by Country5.5.3 Brazil5.6 Middle East and Africa5.6.1 Middle East and Africa Stem Cell Assay Consumption by Application5.6.2 Middle East and Africa Stem Cell Assay Consumption by Countries5.6.3 GCC Countries5.6.4 Egypt5.6.5 South Africa

6 Market Size by Type6.1 Global Stem Cell Assay Production by Type6.2 Global Stem Cell Assay Revenue by Type6.3 Stem Cell Assay Price by Type

7 Market Size by Application7.1 Overview7.2 Global Stem Cell Assay Breakdown Dada by Application7.2.1 Global Stem Cell Assay Consumption by Application7.2.2 Global Stem Cell Assay Consumption Market Share by Application (2013-2018)

8 Manufacturers ProfilesCompany Name8.1.1 Company Details8.1.2 Company Overview8.1.3 Company Stem Cell Assay Production Revenue and Gross Margin (2013-2018)8.1.4 Stem Cell Assay Product Description8.1.5 Recent Developmentand others

9 Production Forecasts9.1 Stem Cell Assay Production and Revenue Forecast9.1.1 Global Stem Cell Assay Production Forecast 2018-20259.1.2 Global Stem Cell Assay Revenue Forecast 2018-20259.2 Stem Cell Assay Production and Revenue Forecast by Regions9.2.1 Global Stem Cell Assay Revenue Forecast by Regions9.2.2 Global Stem Cell Assay Production Forecast by Regions9.3 Stem Cell Assay Key Producers Forecast9.3.1 United States9.3.2 Europe9.3.3 China9.3.4 Japan9.4 Forecast by Type9.4.1 Global Stem Cell Assay Production Forecast by Type9.4.2 Global Stem Cell Assay Revenue Forecast by Type

10 Consumption Forecast10.1 Stem Cell Assay Consumption Forecast by Application10.2 Stem Cell Assay Consumption Forecast by Regions10.3 North America Market Consumption Forecast10.3.1 North America Stem Cell Assay Consumption Forecast by Regions 2018-202510.3.2 United States10.3.3 Canada10.3.4 Mexico10.4 Europe Market Consumption Forecast10.4.1 Europe Stem Cell Assay Consumption Forecast by Regions 2018-202510.4.2 Germany10.4.3 France10.4.4 UK10.4.5 Italy10.4.6 Russia10.5 Asia Pacific Market Consumption Forecast10.5.1 Asia Pacific Stem Cell Assay Consumption Forecast by Regions 2018-202510.5.2 China10.5.3 Japan10.5.4 South Korea10.5.5 India10.5.6 Australia10.5.7 Indonesia10.5.8 Thailand10.5.9 Malaysia10.5.10 Philippines10.5.11 Vietnam10.6 Central & South America Market Consumption Forecast10.6.1 Central & South America Stem Cell Assay Consumption Forecast by Regions 2018-202510.6.2 Brazil10.7 Middle East and Africa Market Consumption Forecast10.7.1 Middle East and Africa Stem Cell Assay Consumption Forecast by Regions 2018-202510.7.2 GCC Countries10.7.3 Egypt10.7.4 South Africa

11 Value Chain and Sales Channels Analysis11.1 Value Chain Analysis11.2 Sales Channels Analysis11.2.1 Stem Cell Assay Sales Channels11.2.2 Stem Cell Assay Distributors11.3 Stem Cell Assay Customers

12 Market Opportunities & Challenges, Risks and Influences Factors Analysis12.1 Market Opportunities and Drivers12.2 Market Challenges12.3 Market Risks/Restraints12.4 Key World Economic Indicators

13 Key Findings in the Global Stem Cell Assay Study

14 Appendix14.1 Research Methodology14.1.1 Methodology/Research Approach14.1.1.1 Research Programs/Design14.1.1.2 Market Size Estimation14.1.1.3 Market Breakdown and Data Triangulation14.1.2 Data Source14.1.2.1 Secondary Sources14.1.2.2 Primary Sources14.2 Author Details14.3 Disclaimer

Read our other Report:-

Global Ultraviolet (UV) Disinfection Equipment Market Competitive Landscape, with advanced Knowledge and Tactics 2021*2027

https://www.openpr.com/news/2315385/global-rutile-market-statastical-data-analysis-by-market-cap

Contact Us:

Syndicate Market Research

244 Fifth Avenue, Suite N202

New York, 10001, United States

Tel: +49-322 210 92714

USA/Canada Toll Free No.1-855-465-4651

Mail id:sales@syndicatemarketresearch.com

Go here to read the rest:
Global Stem Cell Assay Market growth will help industry players with different potential opportunities to explore the market 2021-2027 The Manomet...

Read More...

US trade and investment in Africa – Brookings Institution

Wednesday, August 4th, 2021

Thank you very much, Chairman Van Hollen, Ranking Member Rounds, and distinguished members of the Subcommittee, for your extraordinary leadership on U.S. Trade and Investment with Africa. Your exemplary bipartisan work on Africa inspires many in the U.S. and abroad on how politics can be used to serve the greater good. I am incredibly honored and grateful for the opportunity offered to me by the members of the Senate Foreign Relations Committees (SFRC) Subcommittee on Africa and Global Health Policy to testify on U.S. Trade and Investment in Africa.

I am Landry Sign, Executive Director and Professor at the Thunderbird School of Global Management, Senior Fellow at the Brookings Institutions Africa Growth Initiative in the Global Economy and Development Program, and a member of the World Economic Forums Regional Action Group on Africa, and the World Economic Forums Global Future Council on Agile Governance.

Advancing trade, investment, and technology in Africa offers enormous economic growth and increased prosperity for both regions and is best realized through value-based foreign policy and a market-based model of development, education, and accountability. There is no better time to accelerate U.S. trade and investment in Africa than now. Despite Africas tremendous economic potential, the U.S. has lost substantial ground to traditional and emerging partners, especially China. Indeed, while recent trends indicate that the U.S. engagement with the region has fallen, it has not and should not cede its relationship with the region to other powers.

Importantly, the U.S. can build on new regional momentum to revive and strengthen its partnership with Africa for mutual prosperity, including building on the recent launch of the African Continental Free Trade Area (AfCFTA), and given the promise of the initiatives of the DFC, Prosper Africa, and the post-AGOA 2025 options. To do so means a shift in emphasis in the relationship to one more focused on value-based foreign policy,1and also building upon the areas of strength and convergence with African citizens preferences;2 such as trade, investment, technology, education, accountability, and a market-based model of development.

Borders frequented by trade seldom need soldiers.

-William Schurz, second President of the American Institute for Foreign Trade (now the Thunderbird School of Global Management)

Trade and investment are not just about money and prosperity. They also bring and support peace, stability, and security. In my book Unlocking Africas Business Potential,3I explore key trade and investment trends, opportunities, challenges and strategies, that illustrate the tremendous potential of Africa, and explain the complex competition between emerging and established powers on the continent. The following key trends are critical for policymaking given their implications for trade investment, economic transformation, inclusive prosperity, geopolitical dynamics, and mutual U.S.-Africa interests.

1. Africas economic transformation and business potential are more substantial than most people think: the worlds next growth market. Considered a hopeless continent in 2000 by The Economist, Africa has seen the two best cumulative successive decades of its existence in the 21st century. Trade in and with Africa has grown 300 percent in the last decade, outperforming global averages (196 percent).4It has become home to many of the worlds fastest-growing economies, offering unique opportunities for U.S. trade and investment. Moreover, Africa has tremendous economic potential and offers rewarding opportunities for local and global partners looking for new markets and long-term investments with some of the highest returns, but also the potential to foster economic growth, diversification, job creation, including for women and youth, and improved general welfare.

2. The fast population growth on the continent could be turned into demographic dividends, or threats to global prosperity and stability. Africa was home to 17 percent of the world population in 2020, and is expected to have 26 percent of the global population in 2050 (2.53 billion people).5If Africa is not successfully integrated into the global economy, there could be a major threat to global prosperity and stability. Citizens could be further subject to extreme poverty, fragility, violent extremism, illegal immigration, health challenges, among otherschallenges that many already face on the continent. If our goal is a prosperous and safe world, Africa must not be left behind.

3. The growth of household consumption and business spending: a unique opportunity for U.S. trade and investment. By 2050, Africa will be home to an estimated USD 16.12 trillion of combined consumer and business spending.67 And Africas prosperity can be good for the U.S.: Such growth will offer tremendous opportunities for U.S. businesses in household consumption (USD 8 trillion) in areas such as food and beverages, housing, hospitality and recreation, health care, financial services, education and transport, and consumer goods, but also business to business spending (construction, utility, and transportation, agriculture and agri-processing, wholesale and retail, etc.).

4. The rise of global partnerships and the competition between traditional and new players: an opportunity for the U.S. to build on its sustainable competitive advantage. In 2009, China became the regions prime trading partner. In fact, between 2006 and 2016, Chinas trade with Africa surged, with imports increasing by 233 percent and exports increasing 53 percent, as they did for several other global players as well.8 During the same period, the U.S. lost ground in exports to Africa (-66 percent).9

Chinas influence goes beyond the trade relationship: It is also the top investor in infrastructure, and now is the first destination of English-speaking African students, outperforming the U.S. and the U.K.10

Change (increase) in imports from Africa,

2006 2016

Change (increase) in exports to Africa,

2006 2016

Source: IMF, Direction of Trade Statistics, 2017.11

But the U.S. remains a critical player on the continent, as I mentioned in a recent article: Successes in the past decadesinitiatives such as the African Growth and Opportunity Act (AGOA), the Presidents Malaria Initiative, the Presidents Emergency Plan for AIDS Relief, the Millennium Challenge Corporation, and U.S. trade and investment hubshave generated tremendous opportunities for millions of Africans and Americans. But the current eraand competition from other global powerswill require new ideas and a new approach to several key issues.12 In fact, African countries would often prefer to work with the U.S. given local content regulation rules, more investment in on-the-ground resources, and standards about hiring/training locals. In other words, the U.S. is less extractive and more transparent than numerous other partners.

5. Fast urbanization but also fast rural population growth: By 2030, Africa will be home to 5 cities of more than 10 million inhabitants and 12 other cities of more than 5 million inhabitants.13 Cities in Africa are becoming powerful economic centers, and a city-based approach to foreign policy, but also trade and investment, will be critical to outperform competitors and build mutual prosperity. Contributing to the prosperity of African cities will also make a difference in addressing security challenges.

6. Africa has made tremendous progress in mobilizing resources for infrastructure development, working hard to bridge gaps in ICT, energy, water and sanitation, and transportation. Despite the remaining deficits, the Infrastructure Consortium for Africa (ICA) reported that between 2013 and 2017 the annual funding for infrastructure development in the region was USD 77 billion, about twice as much as the annual funding average of the first six years of the 2000s.14 However, many of these gaps persist. In 2018 the African Development Bank (AfDB) found that Africas infrastructure requirements are between USD 130 and 170 billion a year, leaving a financing gap of USD 68 to108 billion.15 China has played a key role in financing, and has become the largest bilateral infrastructure financer in Africa (Chinese FDI grew 40 percent annually from 2010 to 2020).16 However, the U.S. has the chance to make a monumental difference when it comes to investing in infrastructure development in Africa.

In fact, Africa has one of the fastest-growing, and is the second-largest, mobile phone market in the world.1718 In sub-Saharan Africa alone, there were 477 million mobile subscribers in 2019; by 2025, the region will host 614 million cell phone subscribers, and 475 million mobile internet users.19 The internet is also expected to contribute to at least 5 to 6 percent of Africas total GDP by 2025.20 While the Information and Communication Technology sector is making incredible advancements, water and sanitation, transportation, and energy infrastructure development still needs significant investment. However, this is indicative of positive and extensive investment opportunities that can be undertaken on the African continent.

7. Fast digitalization, increased technological innovation, and an accelerated Fourth Industrial Revolution (4IR): The Fourth Industrial Revolution is characterized by the fusion of the digital, biological, and technological world, and technologies such as artificial intelligence, big data, 5G, drones and automated vehicles, and cloud computing.21 As a world leader in technological innovation, digital transformation, and the Fourth Industrial Revolution, the United States is well-positioned to play a leading role in the African digital space and contribute to Africas pursuit of now-vital technologies.

Indeed, advanced technology can have beneficial spillover effects: For example, in health, countries such as Rwanda and Ghana are using an American drone company Zipline to deliver, in record time, medication, blood, and medical supplies to remote rural areas with limited road accessibility.22 In agriculture, African farmers now have access to affordable precision farming tools that use sensors, satellites, smart devices, and big data technologies to inform every decision. The lending, insurance, and e-commerce opportunities provided by the fintech industry are transforming the lives of all Africans, and not just those in urban centers. These advancements are just the beginning too, as African entrepreneurs are increasingly seeking partners to bring transformative businesses to life. African tech startup funding increased over 40 percent in 2020 to over USD 700 million, a fraction of tech startup funding outside of Africa. Despite such progress, the digital divide remains important and must be bridged to allow inclusive development. During the pandemic, for example, access to school and business on the continent was more complex given the level of internet connectivity, among other limitations. Bridging the digital divide represents an opportunity to both advance U.S. trade and investment in Africa while addressing some of Africas key priorities.

8. Fast regional integration and the African Continental Free Trade Areas: opportunities for a continental engagement. With the signing of the African Continental Free Trade Area (AfCFTA) in 2018, ratification in 2019, and an official launch in January 2021, African growth prospects and business opportunities have been magnified. The continent is giving the world just one more reason to invest in it with the creation of the largest new free-trade zone per number of countries in world, since the creation of the WTO. The AfCFTA will accelerate Africas industrialization as well as incomes, which will lead to the increase of both household consumption and business spending, generating unique opportunities for U.S. trade and investment. Per a World Bank study, the AfCFTA has the potential to lift 30 million people out of extreme poverty, increase the income of 68 million Africans, increase Africas exports by USD 560 billion, and generate USD 450 billion of potential gains for African economies by 2035.23

9. The sustained demand for accountability, democracy, and stability of African citizens, and policy priorities aligned with U.S. core values. Per Afrobarometer surveys, 7 out of 10 Africans support democracy and accountable governance, and approximately two-thirds are opposed to a single party or military government.24 Importantly, areas in which the U.S. has a sustained competitive advantage, given its global leadership in democracy and human rights, and its support for such issues as health and education, are priorities for Africans too.25Given Chinas leadership in infrastructure, the U.S. could grow its footprint in this area but by partnering with other players such as the G7 and the European Union countries. This approach will be welcomed by African citizens, who prefer the U.S. model of development (32 percent) over the Chinse one (23 percent).26

The pandemic has created unique momentum for engagement with Africa. The U.S. should seize this momentum and build on Congress historical bi-partisan support for the region to develop and successfully implement a long-term comprehensive Africa strategy that effectively coordinates action around trade, investment, commerce, and economic growth. This strategy should draw from consultations with African partners and multilaterals, building on areas of sustainable competitive advantages. The strategy should:

a) be rooted in the American values and principles that are aligned with the priorities of African citizens and U.S.-Africa mutual trade and investment interests

b) protect American, African, and global interests by advancing security, stability, and peace through strategic partnerships with African organizations

c) utilize U.S. strengths (digital transformation, Fourth Industrial Revolution, education, creative industries, health, democratic values, etc.) in the context of the new continental trade dynamics brought about by the African Continental Free Trade Areas (AfCFTA).

Importantly, these are areas where the U.S. can still outperform its main competitors such as China or Russia. More specifically, my recommendations to the Subcommittee are as follows:

1. Build on multilateralism and strategic alliances in concert with African partners to advance U.S. and African interests.

Given Africas own emphasis on regionalism, the U.S. would do well to support those efforts and align its own strategy with this perspective in mind. Core African partners include: the African Union, the African Continental Free Trade Area, the Africa Centres for Disease Control and Prevention, the African Union Development Agency, the African Development Bank, among others.

African leaders are looking for partners, especially in terms of trade and investment, more than they need aid. Initiatives from the Millennium Challenge Corporation and the DFC should further support African regional and continental projects, when possible, through regional compacts (MCC, through the 2018 AGOA and MCA Modernization Act, allows investments to be made across borders in Africa, creating opportunities for trade and investment by fostering regional integration and integrated markets).27 For the U.S. to outperform its competitors, it must be on the ground engaging with Africa both at the base but also at the highest levels, building on the Trade and Investment hubs, but going much further.

2. Enhance the effectiveness and better coordinate the action of U.S. agencies acting around trade and investment in Africa by adopting the principle of agile governance.

The U.S. already has phenomenal tools, which in principle, could make a monumental difference if successfully implemented. Prosper Africa holds a lot of potential in terms of trade, investment, shared prosperity, and effective coordination of U.S. agencies, which is not yet realized. The goal of Prosper Africa is to coordinate the tools from across government agencies28 and to foster trade and investment between the U.S. and Africa. Although it is a great idea, many players, especially on the African side, are still hoping for it to achieve its full potential. It will be extremely important to have major wins to reinstate trust with African partners.

I recommend making Prosper Africa more agile in its ability to manage complexity and competition, and appoint a dedicated full-time Chief Executive Officer to assist the current Executive Chairman and Chief Operating Officer, who are doing tremendous work. This new position should have the authority needed to fix the pacing (appropriate speed of action), coordination (legitimate and appropriate coordination), and representation challenges (uniqueness of the voice, communication, and acceptance of the credibility), to deliver exceptional outcomes for U.S. and African businesses, and investors, to achieve mutual prosperity.

3. Redefine the base for new engagement with Africa by appointing a U.S. Special Presidential Envoy for Africa to represent the U.S. at high-level meetings and multiply presidential and high-level visits in Africa.

To stop ceding ground to other powers in Africa, it is crucial that the U.S. reiterate the respect it has for Africa, Africans, and their leaders. Appointing a Special Envoy and reinstating high-level meetings, including presidential visits to the region, between the United States and Africa will send a strong signal. Regular visits by senior U.S. officials, including the President and his cabinet, will help to shift perceptions around Africa, highlighting the continent as a safe, reliable destination for investment. Creating a forum for dialogue between government officials and the SME community will create the opportunity to engage in a systematic and coordinated way.29

Advancing such levels of engagement, with specific actions, will substantially advance mutual interests. The U.S. should build on this to further institutionalize relations with Africa and engagements at the highest level. The success of the U.S.-Africa Business Forum, which did contribute to deals around USD 14 billion between 2014 (first edition) and 2016, with additional deals and commitments of USD 9 billion at the 2016 edition, illustrate the importance of high-level meetings, which should be reinitiated (The first edition of the U.S.-Africa Business Forum was attended by about 50 heads of state and governments, and 150 global CEOs).

This is not just important for African leaders, but also for African citizens who prefer the U.S. model of development compared to any other country.30Strategically seizing such as opportunity to build a long-term sustainable advantage will be critical.

4. For the successful implementation of the AfCFTA and other critical initiatives (post-2025 AGOA, among others) the U.S. should be involved in regular high-level consultations between the United States Trade Representative, the AfCFTA, and the African Union, creating a working group which could define the critical steps forward.

It is important to engage with Africa on the way forward about U.S.-Africa relations, through regular consultations. The AfCFTA offers new opportunities for U.S. businesses to use Africa as a global platform, not just to capitalize on the large African market, but to benefit from the unique advantage provided to sell around the world. The U.S. will also gain market shares, etc. Africa can become the base for U.S. companies to trade not just with Africa, but with the world as well. Africa is not just a market, but also a platform to manufacture and export in other regions of the world. The AGOA Forum provides a platform to discuss these questions in partnership with Africans, but it remains underutilized.

5. The U.S. should capitalize on the AfCFTA that provides the opportunity for the U.S. and the world to finally address the global macroeconomic imbalances which have been reflected in structurally large U.S. current account deficits with a handful of countries largely on account of excessive concentration of supply chains.31

The growth opportunities associated with increasing economies of scale and productivity growth under the AfCFTA provides the path to reorder and diversify the supply chains for greater resilience and while also sustainably addressing the macroeconomic imbalances which have dominated the world economy over the past decades.

Already several countries and corporations are taking advantage of growth opportunities offered by the AfCFTA in the automotive industry. Volkswagen has opened its first car plant in Rwanda.3233 Groupe Peugeot Socit Anonyme has established its first plant to assemble up to 5000 cars a year in Namibia, taking advantage of the free market area to target customers in other countries across the region.34 With its population growth and rising middle class, Africa could well become the largest market for the automotive industry in the coming decades.

These are tremendous opportunities that U.S. carmakers, including those manufacturing less polluting new energy vehicles should be targeting, especially with Africas excess reserves of lithium and coltan which are some of the most important raw materials for a rapidly changing industry.

6. Focus policy action on impact, and on the effective implementation and delivery of initiatives, not just on big policy announcements.

The U.S. should distinguish itself by focusing on successful implementation of existing or new initiatives. For example, the G7 countries and partners have announced an USD 80 billion dollars commitment for Africas private sector for the next five years. How will it be implemented? It is critical to have a clear mechanism for successful implementation that includes sufficient details about the projects. For example, the U.S. and partners should engage with African multilaterals (AfCFTA, AU, etc.) and governments during the policymaking and implementation processes to strategically identify and align objectives. An implementation unit may be created, and a multistakeholder working group to assess and decide on mutual priorities. Similarly, how could the Build Back Better World initiative be successfully implemented, and to what extent will Africa benefit from it? The administration needs to appoint a leader to strategically engage and to have consultations with allies. Bringing the allies together, and giving teeth to the plans that have been put together, will be critical to build sustainable competitive advantage for the U.S.

7. The U.S. should promote commercial diplomacy through an economic strategy that goes beyond the traditional vision of trade and investment. Domestically, the U.S. should increase efforts to document and disseminate the tremendous potential Africa can have for U.S. businesses.

Given that a central goal of Prosper Africa is to double two-way trade, the United States should play a better role in identifying and sharing business and investment opportunities with its domestic businesses and corporations. As large corporations are already better resourced when dealing in Africa, American SMEs are the most likely beneficiaries of Prosper Africawhether through market access or on the supply sideand the DFC should provide them with resources to help trade and invest in a timely manner. For Prosper Africa to benefitboththe U.S. and Africa, each side needs to feel confident in the trading process and consider each other a friend.

Prosper Africa should focus on specific mechanisms aimed at ensuring that American SMEs better understand the dynamics in Africa, to develop a specific interest and attraction on the continent and make others more eager to invest and do business there. This goal can be achieved throughbusiness promotion and facilitation activities encouraging business development as well as corporate diplomacy.

8. The U.S. should capitalize on the African Diaspora, which is heavily represented and active in the U.S., by specifically adopting diaspora commercial diplomacy to foster trade and investment between the U.S. and Africa.

President Biden has made steps in strengthening this relationship through early engagement with the community, but this strategy can be pursued further in regard to trade and investment with Africa in order to distinguish the U.S. from other competitors and accelerate its competitive advantage. The collaborations between African innovators on the continent and African and African-American innovators based in the U.S. have the potential to advance U.S.-Africa relations on several levels.35 Members of the African diaspora have an incredibly valuable understanding of Africa-U.S. cross-cultural engagement, not to mention existing relationships and networks on the continent, making them perhaps the best suited to Prosper Africas efforts to support and facilitate business I mentioned above. Prosper Africa should formalize a relationship with the African diasporas SME community and the continents SME community, and routinely engage as a group, to support the formulation of strategies and mechanisms to increase two-way trade. It has started such an effort, but can do more: For example, in 2019, Brookings hosted a conversation between USAID and members of the diasporas SMEs. It brought to light specific, actionable ways to enhance the programs mechanisms, including the need to expand staff support at trade hubs, expedite DFC loans, and improve data collection and analysis.36 SMEs in Africa are crucial to include in these conversations so that all stakeholders are involved to ensure Prosper Africa designs effective, efficient policies.

9. Accelerate the COVID-19 vaccine strategy and partnerships, and aggressively pursue vaccine diplomacy beyond COVID-19 by supporting the development of a vaccine manufacturing industry in Africa, including investments in human capital and technology development.37

According to the Africa Centers for Disease Control and Prevention (Africa CDC), only 3.19 percent of Africans have received at least one dose of the COVID-19 vaccine as of July 21, 2021.38 A Duke University study estimated that most Africans will not have had an opportunity to receive the COVID-19 vaccine until 2024.39 The devastation of the COVID-19 pandemic, as well as other epidemics in recent years like, has revealed the urgent need for investment in Africas national and continental healthcare systems. Vaccine diplomacy is a crucial first step towards helping Africa recover from the pandemic and prevent the emergence of new variants that might damage the recoveries in other nations.

While it is the right thing to do, it will also support U.S. businesses. Poor healthcare systems threaten Africas industrialization and workforce development, and now is the opportunity for the U.S. to help build equitable health systems and ensure preparedness for future health emergencies. This support should not be limited to loans or donations. Partnerships with academic institutions or public-private partnerships between U.S. and African agencies and firms that create avenues for collaboration, knowledge exchange, and skill and technology development will all be instrumental in strengthening the soft power of the U.S.

Specifically, the U.S. should provide broad technical and financial support for the new African Union-Africa CDC initiative, Partnerships for African Vaccine Manufacturing (PAVM), which aims to build five vaccine-manufacturing research centers over the next 10-15 years. The success of this PAVM initiative would open doors for a transformation of Africas pharmaceutical industry in Africa, a sector that has enormous growth potential. The development must go beyond fill and finish manufacturing, which does little to truly decrease Africas overreliance on foreign suppliers.40

10. Contribute to closing the gap in the physical and digital infrastructure by leveraging existing programs supporting African countries digital transformation strategies.41

The U.S. already has established infrastructure and technology development programs, but is underutilizing them. Such initiatives, especially those that focus on electricity and internet penetration, should be prioritized and fast-tracked.42

Most importantly and prior to even leveraging these existing initiatives, the U.S. should consult and act in partnership with African countries for the investments in major infrastructures, including 5G. For example, an opportunity is within OPIC [now DFC]s Connect Africa initiative, which was launched with a fund of USD 1 billion for transportation, ICT, and value chain development projects.43 The Power Africa initiative has been successful, and augmenting the program now would contribute to repairing and strengthening the U.S.-Africa relationship.44

Furthermore, several African countries are developing and implementing a multi-stakeholder Fourth Industrial Revolution (4IR) national task force or commission to assess country readiness and adopt a comprehensive national strategy. Initiatives such as the Centers for the Fourth Industrial Revolution (South Africa and Rwanda), or the Presidential Commission on the 4IR (South Africa) should be supported and replicated across the continent.

11. The U.S. must continue and increase its support to bridging the infrastructure gap in Africa while advancing trade and investment for mutual prosperity.

This, simultaneously, represents both a way forward to enhance trade and investment while achieving the global public good. In fact, in Sub-Saharan Africa, over 50 percent of people live without access to electricity, more than 70 percent of people live without access to safe drinking water, 69 percent of people live without basic sanitation,45 and 53 percent of the roads are unpaved.46 China has been playing a central role by investing in these areas.

Importantly, the U.S. should differentiate its approach from competitors by emphasizing engagement with African continental organizations (PIDA, the AFDB, the African Development Fund, among others), bilaterallyand more importantly, transparently, with specific countries, and by partnering with allies. The U.S. also could better support capacity building and regional projects through investments, new projects, and partnerships. The U.S. could better partner with Africa to bring its own expertise and knowledge to serve at various phases of project development, such as studies and implementation.47 A long-term partnership will also be key to outperforming other players. The U.S. will see a high return for its investments, as well as geostrategic balance. The U.S. will fill an empty seat, that would otherwise be occupied by other players on the continent.

12. The U.S. can build on higher education, another area of comparative advantage, to provide technical training and reskilling programs through initiatives and agencies to close the digital skills gap and human capital gap (especially for youth and women).48

It is crucial the U.S. expand educational and training opportunities in Africa. The soft skills and development of academic institutions provide the opportunity for the U.S. to lay the foundation for a lasting win-win partnership with Africa, sustained by knowledge exchange and deepening business ties. U.S. policy needs to provide support that incentivizes American universities to open more campuses and degree programs, especially in STEM and technology, throughout Africa. Such programs provide skills in areas critical for the rise of manufacturing industry and effective decentralisation of global supply chains and will be equally beneficial learning opportunities for African students and American students who may study abroad. For example, Carnegie Mellon University has a campus in Rwanda that offers masters programs in information technology and electrical and computer engineering.49 Morgan State University has recently launched a partnership with a university in Ghana, offering two graduate degree programs to students.50 Fast-growing SMEs will be far more likely to evolve and invest in areas where there is a skilled workforce or, at least, resources to support training workers, and added U.S. support could go a long way towards creating an attractive business environment for SME investment. It is indeed an opportunity to establish a long-term partnership of a new nature between U.S. and Africa.

In closing, it is time for U.S. to reverse the trend in the ground lost in Africa as many traditional and emerging global powers are racing to capture Africas tremendous economic potential. The U.S. has a sustained competitive advantage to partner with Africa, advance U.S. trade and investment with the continent, while meeting the majority of Africans priorities. It is up to the U.S. to pursue the recommendations above and seize this unique momentum to advance mutual U.S.-Africa trade and investment interests. By acting promptly, and forging transformative partnerships aligned with African values, the U.S. has the opportunity to not only advance its own interests and contribute to the transformation of a continent that will make up nearly 40 percent of the worlds population by 2100, but also the opportunity to lead the way in building a more prosperous, democratic, secure, and stable world. As mentioned by William Schurz, borders frequented by trade seldom need soldiers.

Thank you very much for your attention and looking forward to your questions.

Continued here:
US trade and investment in Africa - Brookings Institution

Read More...

Stem Cell Banking Market Analysis Revealing Key Drivers & Growth Trends through 2029: CCBC, CBR, ViaCord, Esperite, Vcanbio, and others. KSU |…

Sunday, February 14th, 2021

Stem Cell Banking Market

Stem Cell Banking Market Projections (2020-2029): The Global market Stem Cell Banking theologizes is the most recent of the world business market curves. The report prospects the current and frequent collectors, technological innovations, product supplementation, and their representation of performance broadly across the foreign market.

Thisphenomenalstudy on world-widebusiness includes the results of vital primary and secondary resources. These research findings are accepted by the companys skilled analysts and experts, providing rich in-depth information to associated partners, appraisers as well as captains of the industry.

Get a Sample Copy of this Report @ https://www.regalintelligence.com/request-sample/151669

Prominent players in the industry covered in the report:

CCBC, CBR, ViaCord, Esperite, Vcanbio, Boyalife, LifeCell, Crioestaminal, RMS Regrow, Cordlife Group, PBKM FamiCord, cells4life, Beikebiotech, StemCyte, Cryo-cell, Cellsafe Biotech Group, PacifiCord, Americord, Krio, Familycord, Cryo Stemcell, Stemade Biotech

Market split by Type, can be divided into:Umbilical Cord Blood Stem CellEmbryonic Stem CellAdult Stem CellOther

Market split by Application, can be divided into:Diseases TherapyHealthcare

Market split by Sales Channel, can be divided into:Direct ChannelDistribution Channel

Market segment by Region/Country including:North America (United States, Canada and Mexico)Europe (Germany, UK, France, Italy, Russia and Spain etc.)Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)South America Brazil, Argentina, Colombia and Chile etc.)Middle East & Africa (South Africa, Egypt, Nigeria and Saudi Arabia etc.)

Ourstudypasses through ahaven ofprofound qualitative and quantitativeresearch by industryexperts andprofessionals.Within the reportcontributes a broadperceptionof thepast as well ascurrent marketvista,which implies future statistics and prospects in position with the technical developments over time. Furthermore, the report includes and provides analyses of demand and supply, microeconomic and macroeconomic elements, administrative components and growth indices through the Stem Cell Banking marketplace. The report outlines keytacticsutilized bykey market participants.

Reach us to quote the effective price of this report (UPTO 50% OFF) @ https://www.regalintelligence.com/check-discount/151669

This report provides an accurate understanding and discovery of key geographic areas underway with market Stem Cell Banking, including critical segments and additional segments.The report sets out aspects of territorial growth and the size and scope of the market. Additionally, the report also deals with trading information such as business range, cost and revenue margin as well as gross value. However, this understanding assists readers in the conduct of consumer experts as well as major tactic to reach market share.

Substantivebeneficiaries:

Additional Information:

This reportcontributes to the following:

Important questions answered within this report:

About Us:We, Regal Intelligence, aim to change the dynamics of market research backed by quality data. Our analysts validate data with exclusive qualitative and analytics driven intelligence. We meticulously plan our research process and execute in order to explore the potential market for getting insightful details. Our prime focus is to provide reliable data based on public surveys using data analytics techniques. If you have come here, you might be interested in highly reliable data driven market insights for your product/service,reach us here 24/7.

Mention your Queries here to Get a Call from Our Industry Expert @sales@regalintelligence.com

Contact Us:Regal Intelligence: http://www.regalintelligence.comPh no: +1 231 930 2779 (U.S.) | +44 141 628 8787 (UK)

Follow this link:
Stem Cell Banking Market Analysis Revealing Key Drivers & Growth Trends through 2029: CCBC, CBR, ViaCord, Esperite, Vcanbio, and others. KSU |...

Read More...

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Size Is Expected To Generate Huge Profits and Competitive Outlook – The Courier

Sunday, February 14th, 2021

TheAutologous Stem Cell and Non-Stem Cell Based Therapies Marketresearch report thoroughly explains each and every aspect related to the Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market, which facilitates the reports reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Insight:

Autologous stem cell and non-stem cell based therapies market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 121.68 billion by 2027 growing at a CAGR of 3.75 % in the above-mentioned forecast period. The introduction of novelautologousstem cell based therapies inregenerativemedicine will help in driving the growth of the autologous stem cell and non-stem cell based therapies market.

Get Free Full PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) at: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market#utm_source=KA

This Free report sample includes:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Prominent Key Players Covered in the report:

Antria Inc., BrainStorm Cell Limited, Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC., Fibrocell Science, Inc., thinkBiotech LLC, Caladrius, Opexa Therapeutics, Inc., Orgenesis Inc, Regeneus Ltd,

Key Pointers Covered in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast

TheAutologous Stem Cell and Non-Stem Cell Based Therapies marketreport provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Autologous Stem Cell and Non-Stem Cell Based Therapies market.

Major Regions as Follows:

Get Table Of Contents of This Premium Research For Free @ https://www.databridgemarketresearch.com/toc/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market#utm_source=KA

The report includes accurately drawn facts and figures, along with graphical representations of vital market data. The research report sheds light on the emerging market segments and significant factors influencing the growth of the industry to help investors capitalize on the existing growth opportunities.

How insights and forecast from the reports could benefit you:

Why choose us:

Table Of Contents: Autologous Stem Cell and Non-Stem Cell Based Therapies Market

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Part 06:Market Sizing

Part 07:Five Forces Analysis

Part 08:Market Segmentation

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Part 16:Appendix

Make an Inquiry of theAutologous Stem Cell and Non-Stem Cell Based Therapies Market Report @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market#utm_source=KA

To summarize:

The global Autologous Stem Cell and Non-Stem Cell Based Therapies market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

We are grateful to you for reading our report. If you wish to find more details of the report or want customization, contact us. You can get a detail of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

More here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Size Is Expected To Generate Huge Profits and Competitive Outlook - The Courier

Read More...

Coronavirus Briefing: What Happened Today – The New York Times

Saturday, February 6th, 2021

Good news about vaccines

For once, we have some good news to talk about: the prospect of another vaccine coming online in the U.S., and a long-awaited indication that at least one vaccine reduces transmission, not just the severity of Covid-19.

Lets start with the remarkable turnaround of the experimental vaccine from Novavax, a Maryland-based company that has never before brought a vaccine to market.

Last fall, Novavax postponed U.S. clinical trials because of manufacturing delays, jeopardizing the companys $1.6 billion federal contract and leaving some to wonder whether they should write off the companys shot entirely. In December, Novavax watched from the sidelines as the Pfizer-BioNTech and Moderna vaccines were approved.

But things have changed. Novavax announced last week that its vaccine produced robust protection in a large British trial and that it worked although far less well in a smaller study in South Africa. The company has also been able to quickly recruit volunteers for its U.S. trials because the two authorized vaccines have been difficult to get, and many see the Novavax trial as their best chance to get vaccinated.

So the company now stands a chance of having trial results this spring, with possible government authorization as early as April. If everything goes well, and that is a big if, Novavax could deliver enough additional doses to vaccinate 55 million Americans by the end of June. That would be on top of the 400 million doses that Moderna and Pfizer are contracted to supply the U.S. by the middle of the year enough for 200 million people.

It gets better: Novavax has been laying the international groundwork for the eventual production of two billion doses per year and its vaccine, unlike Moderna and Pfizers, can be stored and shipped at normal refrigeration temperatures.

As for protection against transmission, AstraZeneca recently released a report that offered an answer to one of the pandemics big questions: Will vaccines prevent people from giving the virus to others?

Researchers from the University of Oxford and AstraZeneca have found that not only did their vaccine protect people from serious illness and death but also had the potential to reduce transmission. Swabs taken from trial participants showed a 67 percent reduction in virus being detected among those vaccinated, though scientists warned that the data was preliminary and that masking remained necessary for all.

The AstraZeneca-Oxford vaccine is in U.S. trials, and the company has a deal to supply 300 million doses, enough for another 150 million people.

Heres how the vaccine rollout is going in every state.

Feb. 5, 2021, 4:14 p.m. ET

Dr. Rochelle Walensky, the new director of the Centers for Disease Control and Prevention, laid out her agencys position on opening schools.

There is increasing data to suggest that schools can safely reopen, she said today at a news briefing, adding, Vaccination of teachers is not a prerequisite for safe reopening of schools.

Plenty of teachers dont agree. In some areas, teachers unions say they wont send members back to classrooms without vaccinations. Teachers in 24 states and Washington have begun receiving vaccines, often ahead of people in professions or living situations that may put them at higher risk.

But in some areas, teachers have taught in person for months and educators are not yet eligible for vaccines. And some say that vaccinating teachers might impede reopenings: In California, unions are calling for all teachers to receive vaccines before returning to the classroom, a demand that Gov. Gavin Newsom said could prevent schools from opening this academic year.

Teacher vaccinations remain a moral quandary for states grappling with how to allocate their growing-but-still-limited vaccine supply, especially as more contagious virus variants begin to spread. Incarcerated people, for example, are vulnerable to outbreaks and death, but often fall behind educators. Older adults, too, have sometimes taken a back seat.

In Oregon, teachers will receive vaccines before some residents who are 75 years or older, who are eligible for shots only in certain counties.

Gov. Kate Brown said the move to start vaccinating Oregons teachers was part of her plan to bring students back into the classroom this school year.

For every teacher who is back in the classroom, they help 20, 30, 35 students get their lives back on track, she said. They help ensure 20, 30, 35 kids have access to mental health support. They make sure 20, 30, 35 kids get breakfast and lunch several days a week. And they allow families to know their children are in good hands when they go to work.

Heres a roundup of restrictions in all 50 states.

We live in a small city apartment and were accustomed to going our own ways during the days before Covid. To keep things fresh while we spend so much time at home, we try to stay out of each others way during the day. We also avoid going into the living room. Then when cocktail hour rolls around, we turn on the lights, light the fire, and stream some soft jazz. Meeting there each evening feels as if we have gone out someplace special.

Susan Hanes, Chicago

Let us know how youre dealing with the pandemic. Send us a response here, and we may feature it in an upcoming newsletter.

Sign up here to get the briefing by email.

Email your thoughts to briefing@nytimes.com.

More here:
Coronavirus Briefing: What Happened Today - The New York Times

Read More...

Global Placental Stem Cells (PSCS) Market 2020: Opportunity and Growth Analysis||LifeCell International Pvt. Ltd., StemCyte India Therapeutics Pvt….

Saturday, February 6th, 2021

A wide ranging Placental Stem Cells market report offers the strategists, marketers and senior management with the critical information they need to assess the global market research services market. A good market research report makes it possible to develop strategies such as market segmentation that means identifying specific groups within a market and product differentiation which creates an identity for a product or service that separates it from those of the competitors. With Placental Stem Cells market research report, it gets effortless to identify growth segments for investment as well as benchmark performance against key competitors.

Placentalstem cells(PSCS) marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to growing at a CAGR of 10.25% in the above-mentioned forecast period. Increasing awareness regarding the benefits associates with the preservation of placental derived stem cells will boost the growth of the market.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)@https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-placental-stem-cells-pscs-market&kb

The major players covered in the placental stem cells (PSCS) market report are CBR Systems, Inc, Cordlife India, Cryo-Cell International, Inc., ESPERITE N.V., LifeCell International Pvt. Ltd., StemCyte India Therapeutics Pvt. Ltd, PerkinElmer Inc, Global Cord Blood Corporation., Smart Cells International Ltd., Vita 34, among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Global Placental Stem Cells (PSCS) Market Scope and Market Size

Placental stemcells(PSCS) market is segmented on the basis of service type and application. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Enquire Here Get customization & check discount for report @:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-placental-stem-cells-pscs-market&kb

Placental Stem Cells (PSCS) Market Scope

Placental stem cells (PSCS)market on the basis of countries is segmented into U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa

Table of Contents:

Request for Detailed TOC:https://www.databridgemarketresearch.com/toc/?dbmr=global-placental-stem-cells-pscs-market&kb

Placental Stem Cells (PSCS) Market Scenario

According to Data Bridge Market Research the placental stem cells (PSCS)market in developing regions is witnessing a growth in terms of its adoption rate, due to growing awareness concerning the benefits associates with the conservation of placental derived stem cells. Growing number of diseases along with introduction of hematopoietic stem cell transplantation system are also helping the market to grow. Moreover, rising awareness among the people along with increasing number of applications from emerging economies will further create new opportunities for the growth of the market.

Now the question is which are the regions that placental stem cells (PSCS)market players should target? Data Bridge Market Research has forecasted North America to dominate the market due to the increasing stem cell process along with preferences of personal stem cell banking over public and surging network of stem cell banking services.

Key points in the report

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailingsopan.gedam@databridgemarketresearch.com. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:Corporatesales@databridgemarketresearch.com

More:
Global Placental Stem Cells (PSCS) Market 2020: Opportunity and Growth Analysis||LifeCell International Pvt. Ltd., StemCyte India Therapeutics Pvt....

Read More...

India Cord Stem Cell Banking Market Witness an Outstanding Growth and Strong Revenue and Forecast to 2026 KSU | The Sentinel Newspaper – KSU | The…

Saturday, January 23rd, 2021

TheIndia Cord Stem Cell Banking Marketresearch report thoroughly explains each and every aspect related to the Global India Cord Stem Cell Banking Market, which facilitates the reports reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business.

India Cord Stem Cell Banking Market Insight:

Europe contrast and imaging agents in interventional X-ray market is projected to register a healthy CAGR of 5.8 % in the forecast period 2019 to 2026.

Get Free Full PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) at:https://www.databridgemarketresearch.com/request-a-sample/?dbmr=india-cord-stem-cell-banking-market

This Free report sample includes:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Prominent Key Players Covered in the report:

Cordlife Group Limited, LifeCell, Mycord (CelluGen Biotech Pvt. Ltd.), Reliance Life Sciences, Cryoviva India, Global Cord Blood Corporation, Cryo-Cell International, Inc., REGROW BIOSCIENCES PVT LTD, ReeLabs Pvt. Ltd. and others.

Key Pointers Covered in the India Cord Stem Cell Banking Market Industry Trends and Forecast

TheIndia Cord Stem Cell Banking marketreport provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the India Cord Stem Cell Banking market.

Major Regions as Follows:

Get Table Of Contents of This Premium Research For Free @https://www.databridgemarketresearch.com/toc/?dbmr=india-cord-stem-cell-banking-market

The report includes accurately drawn facts and figures, along with graphical representations of vital market data. The research report sheds light on the emerging market segments and significant factors influencing the growth of the industry to help investors capitalize on the existing growth opportunities.

How insights and forecast from the reports could benefit you:

Why choose us:

Table Of Contents: India Cord Stem Cell Banking Market

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Part 06:Market Sizing

Part 07:Five Forces Analysis

Part 08:Market Segmentation

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Part 16:Appendix

Make an Inquiry of theIndia Cord Stem Cell Banking Market Report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=india-cord-stem-cell-banking-market

To summarize:

The global India Cord Stem Cell Banking market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

We are grateful to you for reading our report. If you wish to find more details of the report or want customization, contact us. You can get a detail of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

View original post here:
India Cord Stem Cell Banking Market Witness an Outstanding Growth and Strong Revenue and Forecast to 2026 KSU | The Sentinel Newspaper - KSU | The...

Read More...

Global Placental Stem Cells (PSCS) Market Is Expected To Gain Market Growth In The Forecast Period Of 2020 To 2027||ESPERITE NV, LifeCell…

Saturday, January 23rd, 2021

Placentalstem cells(PSCS) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to growing at a CAGR of 10.25% in the above-mentioned forecast period. Increasing awareness regarding the benefits associates with the preservation of placental derived stem cells will boost the growth of the market.

Global placental stem cells market research report helps staying informed about the trends and opportunities in the Healthcare industry very easily and quickly by saving a lot of time. As this market research report is formulated by taking into account and thoroughly understanding specific requirements of the business, it results into an excellent outcome. Besides, the report systematically gathers the information about influencing factors for the Healthcare industry which contains customer behaviour, emerging trends, product usage, and brand positioning. The vital market insights of the placental stem cells business report helps business make data-driven decisions as well as guarantees maximum return on investment (ROI).

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-placental-stem-cells-pscs-market&kb

The major players covered in the placental stem cells (PSCS) market report are CBR Systems, Inc, Cordlife India, Cryo-Cell International, Inc., ESPERITE N.V., LifeCell International Pvt. Ltd., StemCyte India Therapeutics Pvt. Ltd, PerkinElmer Inc, Global Cord Blood Corporation., Smart Cells International Ltd., Vita 34, among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Placental Stem Cells (PSCS) Market Scenario

According to Data Bridge Market Research the placental stem cells (PSCS)market in developing regions is witnessing a growth in terms of its adoption rate, due to growing awareness concerning the benefits associates with the conservation of placental derived stem cells. Growing number of diseases along with introduction of hematopoietic stem cell transplantation system are also helping the market to grow. Moreover, rising awareness among the people along with increasing number of applications from emerging economies will further create new opportunities for the growth of the market.

Now the question is which are the regions that placental stem cells (PSCS)market players should target? Data Bridge Market Research has forecasted North America to dominate the market due to the increasing stem cell process along with preferences of personal stem cell banking over public and surging network of stem cell banking services.

Global Placental Stem Cells (PSCS) Market Scope and Market Size

Placental stemcells(PSCS) market is segmented on the basis of service type and application. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Enquire Here Get customization & check discount for report @: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-placental-stem-cells-pscs-market&kb

Placental Stem Cells (PSCS) Market Scope

Placental stem cells (PSCS)market on the basis of countries is segmented into U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa

Table of Contents:

Request for Detailed TOC: https://www.databridgemarketresearch.com/toc/?dbmr=global-placental-stem-cells-pscs-market&kb

Key points in the report

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailingsopan.gedam@databridgemarketresearch.com. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email: Corporatesales@databridgemarketresearch.com

Read the rest here:
Global Placental Stem Cells (PSCS) Market Is Expected To Gain Market Growth In The Forecast Period Of 2020 To 2027||ESPERITE NV, LifeCell...

Read More...

Massive Growth Of Bone Marrow Market Size Strong Revenue and Competitive Outlook KSU | The Sentinel Newspaper – KSU | The Sentinel Newspaper

Saturday, January 23rd, 2021

TheBone Marrow Marketresearch report thoroughly explains each and every aspect related to the Global Bone Marrow Market, which facilitates the reports reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business.

Bone Marrow Market Insight:

Global bone marrow market is expected to register a substantial CAGR of 6.05% in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. This rise in market value can be attributed to the rising levels of success rates with these procedures which are expected to result in higher adoption rates along with the rising levels of commercialization by the various research companies regarding their products & services.

Get Free Full PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) at: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bone-marrow-market

This Free report sample includes:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Prominent Key Players Covered in the report:

Abbott; QIAGEN; Diazyme Laboratories, Inc.; Sanofi; CSL; STEMCELL Technologies Inc.; Lonza; HemaCare; PromoCell GmbH; Mesoblast Ltd; Lifeline Cell Technology, an International Stem Cell Company; Cellular Dynamics International, Inc.; ReachBio LLC; ATCC; Merck KGaA; Discovery Life Sciences; AllCells; ReeLabs Pvt. Ltd. and Gamida Cell.

Key Pointers Covered in the Bone Marrow Market Industry Trends and Forecast

The Bone Marrow market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Bone Marrow market.

Major Regions as Follows:

Get Table Of Contents of This Premium Research For Free @ https://www.databridgemarketresearch.com/toc/?dbmr=global-bone-marrow-market

The report includes accurately drawn facts and figures, along with graphical representations of vital market data. The research report sheds light on the emerging market segments and significant factors influencing the growth of the industry to help investors capitalize on the existing growth opportunities.

How insights and forecast from the reports could benefit you:

Why choose us:

Table Of Contents: Bone Marrow Market

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers and Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

Make an Inquiry of theBone Marrow Market Report @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-bone-marrow-market

In the end, the Bone Marrow market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the global Bone Marrow market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

We are grateful to you for reading our report. If you wish to find more details of the report or want customization, contact us. You can get a detail of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

Follow this link:
Massive Growth Of Bone Marrow Market Size Strong Revenue and Competitive Outlook KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper

Read More...

Stem Cell Characterization Kits Market Trends, Forecast, and Analysis by 2018 to 2026 NeighborWebSJ – NeighborWebSJ

Saturday, January 23rd, 2021

Mass technological transformation of the global healthcare industry has left key market participants struggling to traverse the complexities of medical and life sciences. Given the shifting dynamics of the global healthcare sector, pharma and biotech companies are taking measured efforts to improve patient outcomes in an effective manner, while keeping a careful watch on the bottom line.

Much is being said about Artificial Intelligence taking over manual back office and supply chain operations in the healthcare ecosystem, threatening to replace physicians from critical claims processing roles. This might put pressure on pharmaceutical companies to ensure readiness to the new technology.

Big data and analytics will drive patient outcomes in a big way, and the coming years will witness a growing emphasis on healthcare service providers in the business of gathering and processing patient health data.

Creating outcome-oriented financial models to maximize reimbursements in value-based healthcare will be a strategic shift from the traditional fees-for-services model. This implies that pharmaceutical companies will need to devise appropriate measures to optimize costs and improve the quality of patient care.

Fact.MR has adopted multi-disciplinary approach to shed light on the evolution of the Stem Cell Characterization Kits Market during the historical period. The study presents a deep-dive assessment of the current growth dynamics, major avenues in the estimation year of 2019, and key prospects over the forecast period 2018 to 2026.

Extensive rounds of primary and a comprehensive secondary research have been leveraged by the analysts at Fact.MR to arrive at various estimations and projections of the Stem Cell Characterization Kits Market, both at global and regional levels. The analysts have used numerous industry-wide prominent business intelligence tools to consolidate facts, figures, and market data into revenue estimations and projections in the Stem Cell Characterization Kits Market.

The insights and analytics on the Stem Cell Characterization Kits Market span several pages. These are covered in numerous sections, including, drivers and restraints, challenges and opportunities, regional segmentation and opportunity assessment, end-use/application prospects analysis, and competitive landscape assessment. Key stakeholders in the Stem Cell Characterization Kits Market including industry players, policymakers, and investors in various countries have been continuously realigning their strategies and approaches to implement them in order to tap into new opportunities. Many in recent months have overhauled their strategies to remain agile in the backdrop of worldwide disruptions caused by the COVID-19 pandemic.

The following insights and evaluations are worth knowing for any market participant, helping them in ascertaining the prevailing dynamics and the future trajectories of the Stem Cell Characterization Kits Market. They are a part of the estimations of the opportunities in various segments.

Regional Segments Analyzed Include:

The Report Covers Exhaustive Analysis On:

After reading the Stem Cell Characterization Kits Market report, readers get insight into:

The Stem Cell Characterization Kits Market report offers detailed assessments and quantitative evaluations that shed light on numerous key aspects that have shaped its evolution over the historical period. In coming years, some of the key aspects that will shape the growth prospects during the forecast period are objectively covered in the study.

Some important questions that the Stem Cell Characterization Kits Market report tries to answer exhaustively are:

Why Choose Fact.MR?

About Us

Fact.MR is an independent, pure play market intelligence firm incorporated with an objective to deliver high quality, customized market research solutions that help our clients successfully go to the market equipped with actionable insights capable of impacting crucial business decisions.

Contact UsUnit No: AU-01-H Gold Tower (AU),Plot No: JLT-PH1-I3A,Jumeirah Lakes Towers, Dubai,United Arab EmiratesPh. No: +353-1-6111-593

https://neighborwebsj.com/

See the rest here:
Stem Cell Characterization Kits Market Trends, Forecast, and Analysis by 2018 to 2026 NeighborWebSJ - NeighborWebSJ

Read More...

Stem Cell Therapy Market 2021-2026 Insights on Type, Region and Comprehensive Analysis of the Development Factors in the Industry Reviewindependent -…

Saturday, January 23rd, 2021

The demand within the global Stem Cell Therapy Market is a function of advancements in research and analysis. The industrial dynamics of the Stem Cell Therapy market have improved in recent times, as several government policies favour the manufacturing of Stem Cell Therapy products. There is little contention about the need for acquiring government issuances and authentications in order to sell Stem Cell Therapy products across free markets. Furthermore, the vendors operating in this market are also required to take cognizance of the trade and sales laws imposed by the state. Therefore, it is crucial for the leading market players to ensure seamless adherence to state policies and laws. Rest assured, the global Stem Cell Therapy market is expected to earn fresh revenues in the times to follow.

Get PDF Sample Report of Stem Cell Therapy (COVID-19 Version) Market 2021, Click Here @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=Pallavi

The vendor landscape of the global Stem Cell Therapy market displays a fragmented picture as several new and old vendors coexist across this market. Despite the formidable foothold of the established vendors, entry of new vendors is projected to disrupt the dynamic of market growth. Furthermore, in the absence of alternatives, consumers are compelled to resort to the use of Stem Cell Therapy products. Henceforth, it is safe to expect that the global Stem Cell Therapy market would tread along a lucrative trajectory in the times to follow.

Read complete report with TOC at: https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=Pallavi

Impact of COVID-19 on Stem Cell Therapy Market

The report also includes the impact of ongoing global crisis i.e. COVID-19 on the Stem Cell Therapy Market and what the future holds for it. It provides an analysis of the effects of the pandemic on the global economy. The outbreak has directly disturbed the demand and supply chain. The report also analyzes the financial impact on firms and financial markets. Adroit Market Research has gathered insights from several delegates of the industry and got involved in the primary and secondary research to provide the clients with data and strategies to combat the market challenges during and after COVID-19 pandemic.

The study, among other macroeconomic uncertainties, has made a granular assessment of the repercussions of the Covid-19 pandemic-led economic disruption. Also, it has presented the planning and strategic overhaul some of the prominent companies in the Stem Cell Therapy Market have undergone in recent months. The study offers a close look at the business models that emerged due to Covid-19 and those that are likely to stay at least for the next few years.

The Global Stem Cell Therapy is segmented by:

By Type

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

By Application

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

Points Covered in the Report:

1.Readers with the aid of this versatile research report are aided with a new approach to view the market at a granular standpoint with vivid description of the vendor landscape, encompassing details such as next line of investments, pipeline projects, real time status of the current Stem Cell Therapy market spectrum and the like.2.Other requisite information such as overall all positioning of the key vendors on the competition graph, threat probabilities of new market aspirants and versatile details on new product development and realignment of objectives are all touched upon in this report.3.The report in its further revelations also highlights details entailing various regional, local and global developments maneuvered by key veterans, as well as other contributing players willing to establish strong footing amidst neck-deep competition.4.The report is wholly equipped with magnanimous inputs regarding the constant promotional and advertising activities being harnessed by leading players to entice healthy and desirable customer inclination.5.The report also houses crucial and real-time data, elaborating on production strategies, production innovations, versatility in application as well as other auxiliary information citing regulatory alterations, government initiatives and other vital funding initiatives.

The report at a glance

The Stem Cell Therapy market report focuses on the economic developments and consumer spending trends across different countries for the forecast period 2021 to 2027. The research further reveals which countries and regions will have a better standing in the years to come. Apart from this, the study talks about the growth rate, market share as well as the recent developments in the Stem Cell Therapy industry worldwide. Besides, the special mention of major market players adds importance to the overall market study.

Market segment by Region/Country including:

1.North America (United States, Canada and Mexico)2.Europe (Germany, UK, France, Italy, Russia and Spain etc.)3.Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)4.South America Brazil, Argentina, Colombia and Chile etc.)5.Middle East & Africa (South Africa, Egypt, Nigeria and Saudi Arabia etc.)

If you have any questions on this report, please reach out to us @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=Pallavi

About Us :

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Visit link:
Stem Cell Therapy Market 2021-2026 Insights on Type, Region and Comprehensive Analysis of the Development Factors in the Industry Reviewindependent -...

Read More...

Page 11234..1020..»


2022 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick